Methods for Treating Hyperpigmentation Disorders

Topical application of a selective PKCβ inhibitor like ruboxistaurin provides a targeted and less toxic approach to reducing skin pigmentation in hyperpigmentation disorders, achieving up to 99% inhibition of melanin formation.

JP7583777B2Active Publication Date: 2024-11-14DERMBIONT INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022178398
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-12-19
Filing Date
2022-11-07
Publication Date
2024-11-14
Estimated Expiration
2037-12-19

AI Technical Summary

Technical Problem

Current treatments for hyperpigmentation disorders, such as melasma, are only partially effective and often toxic, leading to a need for more targeted and less harmful methods to reduce skin pigmentation.

Method used

Administering a selective inhibitor of protein kinase C beta (PKCβ), such as ruboxistaurin, topically, intradermally, or subcutaneously to inhibit melanogenesis and reduce skin pigmentation.

Benefits of technology

The method effectively reduces skin pigmentation by inhibiting PKCβ, offering a more targeted and less toxic alternative to existing treatments, with potential for significant reduction in melanin formation up to 99%.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583777000019
    Figure 0007583777000019
  • Figure 0007583777000020
    Figure 0007583777000020
  • Figure 0007583777000021
    Figure 0007583777000021
Patent Text Reader

Abstract

Compositions are provided for treating one or more symptoms associated with hyperpigmentation disorders. The present invention provides a composition containing ruboxistaurin or a salt thereof, which further contains an antioxidant and / or glycol.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims priority to U.S. Application No. 62 / 435,970, filed December 19, 2016, the contents of which are incorporated herein by reference in their entirety. [Background technology]

[0002] Melanin is a complex biopolymer that gives skin and hair their natural pigment; generally, the more melanin, the darker the skin and hair. Melanin is produced by melanocytes and is derived from the amino acid tyrosine. The first and rate-limiting step in the biosynthesis of melanin is the catalysis of L-3,4-dihydroxyphenylalanine by the oxidase tyrosinase, which is activated via phosphorylation by protein kinase C isoform β (PKCβ). Tyrosinase is expressed exclusively in melanocytes. Skin pigmentation varies, among other things, with the number and distribution of melanin-containing melanosomes, and reflects the activity of tyrosinase in recent weeks. Without wishing to be bound by theory, it is believed that when tyrosinase is mutated, e.g. non-functional, as in albinism disorders, melanin production is reduced, e.g. minimal or no melanin is produced.

[0003] Skin hyperpigmentation conditions are characterized by a generalized or localized increase in an individual's normal skin color. Skin hyperpigmentation conditions include melasma, e.g., post-inflammatory hyperpigmentation, discoid lupus erythematosus, and other forms of increased epithelial melanin deposition. For example, melasma is characterized by dark, irregular, clearly demarcated hyperpigmented spots and areas commonly found on the upper cheeks, upper nose, lips, and forehead, which appear gradually over time. Hyperpigmentation may also appear on other parts of the body, especially sun-exposed areas such as the forearms and neck. Current treatments for melasma include hydroquinone (HQ), azelaic acid, and kojic acid, all nonselective toxins that reduce tyrosinase activity. These current treatments are only partially effective and / or toxic; sometimes causing permanent loss of pigment or ochronosis (a permanent skin pigmentation condition characterized by erythema, blue-black skin pigmentation, and papulonodular lesions) due to death of melanocytes. Thus, there is a need for new methods for treating hyperpigmentation disorders such as melasma that are more effective, targeted, and limit these serious side effects. Summary of the Invention

[0004] The present invention relates, inter alia, to methods for treating hyperpigmentation conditions or generally reducing unwanted pigmentation. For example, the present invention provides a novel method for treating hyperpigmentation conditions, comprising administering to a subject an effective amount of a compound that selectively inhibits PKCβ non-systemically (e.g., topically, intradermally or subcutaneously). The present invention also relates, inter alia, to novel methods for reducing skin pigmentation. For example, the present invention provides a novel method for reducing skin pigmentation, comprising administering to a subject's skin (e.g., a predetermined area of ​​the subject's skin) an effective amount of a compound that selectively inhibits PKCβ non-systemically (e.g., topically, intradermally or subcutaneously).

[0005] In certain aspects, the invention provides a method of reducing skin pigmentation in a subject, comprising non-systemically (e.g., topically, intradermally or subcutaneously) administering to the subject an effective amount of a compound that selectively inhibits PKCβ, thereby reducing skin pigmentation in the subject.

[0006] In some embodiments, reducing skin pigmentation includes reducing skin pigmentation associated with a skin hyperpigmentation condition, hi some embodiments, reducing skin pigmentation includes reducing skin pigmentation in a healthy or non-disease state, such as unwanted healthy skin pigmentation.

[0007] In some embodiments, the compound comprises a compound of formula I (e.g., as described herein). In some embodiments, the compound comprises a compound of formula Id (e.g., as described herein). In some embodiments, the compound comprises a compound of formula If-1 (e.g., as described herein). In some embodiments, the compound comprises a compound of formula If-2 (e.g., as described herein). In some embodiments, the compound comprises ruboxistaurin or a salt thereof, such as ruboxistaurin mesylate. In some embodiments, the compound comprises ruboxistaurin mesylate. In some embodiments, the compound comprises ruboxistaurin formulated as a gel. In some embodiments, the compound comprises at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5% ruboxistaurin, for example, formulated as a gel. In some embodiments, the compound is administered topically. In some embodiments, the compound is administered intradermally. In some embodiments, the compound is administered subcutaneously.

[0008] In some embodiments, A compound of formula I (e.g., as described herein); A compound of formula Id (e.g. as described herein); A compound of formula If-1 (e.g., as described herein); A compound of formula If-2 (e.g., as described herein); Ruboxistaurin or a salt thereof; or Ruboxistaurin Mesylate Compounds comprising the compound reduce, e.g., inhibit, melanogenesis, e.g., skin darkening or pigmentation.

[0009] In some embodiments, melanogenesis is induced, for example, by UV exposure, for example, sun exposure or tanning reaction.In some embodiments, the compound reduces, for example inhibits, melanogenesis, for example, skin darkening and pigmentation, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100%.In some embodiments, the reduction, for example inhibition, of melanogenesis is measured by the assay of Example 2.

[0010] In some embodiments, the compound comprises the compound of formula I, the compound of formula Id, the compound of formula If-1, the compound of formula If-2, ruboxistaurin or its salt, such as ruboxistaurin mesylate, formulated as, for example, a gel.In some embodiments, the formulation, such as a gel formulation, comprises at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5% of ruboxistaurin or its salt, such as ruboxistaurin mesylate.In some embodiments, the formulation, such as a gel formulation, is suitable for topical administration.

[0011] In other embodiments, the compound comprises a bisindolylmaleimide or a derivative thereof. In certain embodiments, the bisindolylmaleimide derivative is selected from bisindolylmaleimide I (BIM-1) or bisindolylmaleimide II (BIM-2) or a salt thereof.

[0012] In some embodiments, administering includes contacting a device, e.g., a skin patch, containing the compound with the subject, e.g., the skin of the subject. In some embodiments, administering includes pre-treating the skin, e.g., with a Fraxel laser or microneedles, e.g., to enhance penetration of the compound into the skin.

[0013] In some embodiments, the compound is administered in a pharmaceutical composition.

[0014] In some embodiments, the hyperpigmentation condition is selected from melasma, post-inflammatory hyperpigmentation, discoid lupus erythematosus, phytophotodermatitis, lentigines (e.g., senile lentigo), birthmarks, cafe au lait spots, acanthosis nigricans, burn-associated hyperpigmentation, drug-induced hyperpigmentation (e.g., sulfonamide-, tetracycline-, NSAID-, barbiturate-, and carbamazepine-induced hyperpigmentation), injury-induced hyperpigmentation, primary biliary cirrhosis-associated hyperpigmentation, Addison's disease-associated hyperpigmentation, pigmented nevi, ephelides, seborrheic keratosis, skin cancer-associated hyperpigmentation, infection-associated hyperpigmentation (e.g., tinea versicolor, erythrasma), eczema, photocontact dermatitis, ichthyosis, neurofibromatosis, or hyperpigmentation associated with ultraviolet (UV) radiation, e.g., sun exposure or sunburn reaction.

[0015] In some embodiments, the hyperpigmentation condition is melasma. In some embodiments, the hyperpigmentation condition is post-inflammatory hyperpigmentation. In some embodiments, the hyperpigmentation condition is a lentigo, e.g., age spots. In some embodiments, the hyperpigmentation condition is a sunburn reaction.

[0016] In some embodiments, compound is administered in combination with additional agent, for example, therapeutic agent or cosmetic agent.In some embodiments, one or more additional agents, for example, therapeutic agent, are selected from hydroquinone, tretinoin, corticosteroid, azelaic acid, kojic acid, retinoid, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide, titanium dioxide, cosmetic agent, pigment, fragrance, sunscreen, foaming surfactant, vitamin, hydroxy acid, antioxidant, retinoid or moisturizing agent.

[0017] In some embodiments, one or more additional agents are administered locally. In some embodiments, the additional agent is co-applied with the compound. In some embodiments, the additional agent and the compound are applied to a common area, but at different times. In some embodiments, the additional agent and the compound are included in the same unit dosage form. In some embodiments, the additional agent and the compound are placed in different unit dosage forms. In some embodiments, a second or multiple additional agents are administered. In some embodiments, a second administration of the compound is administered. In some embodiments, a third administration of the compound is administered.

[0018] In some embodiments, it is administered multiple times in 7 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, it is administered multiple times in 14 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, it is administered multiple times in 21 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, the compound is administered multiple times within a 30 day period, e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times.

[0019] In some embodiments, compound is administered every day, every other day, every week or every month.In some embodiments, compound is administered every day for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months or longer.In some embodiments, compound is administered every day for at least 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years or 10 years.

[0020] In some embodiments, the subject has been previously treated with the compound, for example, for at least 1 month, 6 months, 12 months, 24 months, 36 months or 48 months. In some embodiments, the subject has been previously treated with the compound one or more times, for example, at least 2, 10, 20, 30, 40, 50, 100, 200, 300 or 500 times.

[0021] In some embodiments, the method includes applying the compound to a predetermined area of ​​the body, e.g., a predetermined area of ​​skin, e.g., as described herein. In some embodiments, the method includes applying the compound to an area of ​​skin where a hyperpigmentation condition is present. In some embodiments, the method includes applying the compound to an area adjacent to an area of ​​skin where a hyperpigmentation condition is present. In some embodiments, the method includes applying the compound to the face, arms, back, or other areas where unwanted or otherwise excessive hyperpigmentation is present.

[0022] In some embodiments, the invention provides a method for reducing skin pigmentation associated with a skin hyperpigmentation condition in a subject, comprising topically administering an effective amount of ruboxistaurin to an area of ​​the subject's skin (e.g., a predetermined area of ​​the subject's skin), thereby reducing the subject's skin pigmentation compared to the skin pigmentation prior to administration of the compound. In some embodiments, the hyperpigmentation condition comprises melasma.

[0023] In some embodiments, the compound comprises a compound of formula I (e.g., as described herein). In some embodiments, the compound comprises a compound of formula Id (e.g., as described herein). In some embodiments, the compound comprises a compound of formula If-1 (e.g., as described herein). In some embodiments, the compound comprises a compound of formula If-2 (e.g., as described herein). In some embodiments, the compound comprises ruboxistaurin or a salt thereof, such as ruboxistaurin mesylate. In some embodiments, the compound comprises ruboxistaurin mesylate. In some embodiments, the compound comprises ruboxistaurin formulated as a gel. In some embodiments, the compound comprises at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5% ruboxistaurin, for example, formulated as a gel. In some embodiments, the compound is administered topically. In some embodiments, the compound is administered intradermally. In some embodiments, the compound is administered subcutaneously.

[0024] In some embodiments, A compound of formula I (e.g., as described herein); A compound of formula Id (e.g. as described herein); A compound of formula If-1 (e.g., as described herein); A compound of formula If-2 (e.g., as described herein); Ruboxistaurin or a salt thereof; or Ruboxistaurin Mesylate Compounds comprising the compound reduce, e.g., inhibit, melanogenesis, e.g., skin darkening or pigmentation.

[0025] In some embodiments, melanogenesis is induced, for example, by UV exposure, e.g., sun exposure or tanning reaction). In some embodiments, the compound reduces, e.g., inhibits, melanogenesis, e.g., skin darkening and pigmentation, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100%. In some embodiments, the reduction, e.g., inhibition, of melanogenesis is measured by the assay of Example 2.

[0026] In some embodiments, the compound comprises the compound of formula I, the compound of formula Id, the compound of formula If-1, the compound of formula If-2, ruboxistaurin or its salt, for example ruboxistaurin mesylate, formulated as gel.In some embodiments, the formulation, for example, the gel formulation, comprises at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5% of ruboxistaurin or its salt, for example ruboxistaurin mesylate.In some embodiments, the formulation, for example, the gel formulation, is suitable for topical administration.

[0027] In other embodiments, the compound comprises a bisindolylmaleimide or a derivative thereof. In certain embodiments, the bisindolylmaleimide derivative is selected from bisindolylmaleimide I (BIM-1) or bisindolylmaleimide II (BIM-2) or a salt thereof.

[0028] In some embodiments, compound is administered in combination with additional agent, for example, therapeutic agent or cosmetic agent.In some embodiments, one or more additional agents, for example, therapeutic agent, are selected from hydroquinone, tretinoin, corticosteroid, azelaic acid, kojic acid, retinoid, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide, titanium dioxide, cosmetic agent, pigment, fragrance, sunscreen, foaming surfactant, vitamin, hydroxy acid, antioxidant, retinoid or moisturizing agent.

[0029] In some embodiments, one or more additional agents are administered locally. In some embodiments, the additional agent is co-applied with the compound. In some embodiments, the additional agent and the compound are applied to a common area, but at different times. In some embodiments, the additional agent and the compound are included in the same unit dosage form. In some embodiments, the additional agent and the compound are placed in different unit dosage forms. In some embodiments, a second or multiple additional agents are administered. In some embodiments, a second administration of the compound is administered. In some embodiments, a third administration of the compound is administered.

[0030] In some embodiments, it is administered multiple times in 7 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, it is administered multiple times in 14 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, it is administered multiple times in 21 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, the compound is administered multiple times within a 30 day period, e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times.

[0031] In some embodiments, compound is administered every day, every other day, every week or every month.In some embodiments, compound is administered every day for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months or longer.In some embodiments, compound is administered every day for at least 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years or 10 years.

[0032] In some embodiments, the subject has been previously treated with the compound, for example, for at least 1 month, 6 months, 12 months, 24 months, 36 months or 48 months. In some embodiments, the subject has been previously administered one or more doses of the compound, for example, at least 2, 10, 20, 30, 40, 50, 100, 200, 300 or 500 doses of the compound.

[0033] In some embodiments, the method includes applying the compound to a predetermined area of ​​the body, such as a predetermined area of ​​the skin. In some embodiments, the method includes applying the compound to an area of ​​the skin where a hyperpigmentation condition is present. In some embodiments, the method includes applying the compound to an area adjacent to an area of ​​the skin where a hyperpigmentation condition is present. In some embodiments, the method includes applying the compound to the face, arms, back, or other areas where unwanted or otherwise excessive hyperpigmentation is present.

[0034] In some embodiments, the invention provides a method of reducing skin pigmentation associated with a skin hyperpigmentation condition in a subject, comprising topically administering an effective amount of ruboxistaurin to an area of ​​the subject's skin (e.g., a predetermined area of ​​the subject's skin), thereby reducing the subject's skin pigmentation compared to the skin pigmentation prior to administration of the compound.

[0035] In some embodiments, the compound comprises a compound of formula I (e.g., as described herein). In some embodiments, the compound comprises a compound of formula Id (e.g., as described herein). In some embodiments, the compound comprises a compound of formula If-1 (e.g., as described herein). In some embodiments, the compound comprises a compound of formula If-2 (e.g., as described herein). In some embodiments, the compound comprises ruboxistaurin mesylate. In some embodiments, the compound comprises ruboxistaurin. In some embodiments, the compound comprises ruboxistaurin or a salt thereof, e.g., ruboxistaurin mesylate, formulated, e.g., as a gel. In some embodiments, the compound comprises at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, or 1.5% ruboxistaurin or a salt thereof, e.g., ruboxistaurin mesylate, formulated, e.g., as a gel. In some embodiments, the compound is administered topically. In some embodiments, the compound is administered intradermally. In some embodiments, the compound is administered subcutaneously.

[0036] In some embodiments, A compound of formula I (e.g., as described herein); A compound of formula Id (e.g. as described herein); A compound of formula If-1 (e.g., as described herein); A compound of formula If-2 (e.g., as described herein); Ruboxistaurin or a salt thereof; or Ruboxistaurin Mesylate Compounds comprising the compound reduce, e.g., inhibit, melanogenesis, e.g., skin darkening or pigmentation.

[0037] In some embodiments, melanogenesis is induced, for example, by UV exposure, e.g., sun exposure or tanning reaction). In some embodiments, the compound reduces, e.g., inhibits, melanogenesis, e.g., skin darkening and pigmentation, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100%. In some embodiments, the reduction, e.g., inhibition, of melanogenesis is measured by the assay of Example 2.

[0038] In some embodiments, the compound comprises the compound of formula I, the compound of formula Id, the compound of formula If-1, the compound of formula If-2, ruboxistaurin or its salt, for example ruboxistaurin mesylate, formulated as gel.In some embodiments, the formulation, for example, the gel formulation, comprises at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5% of ruboxistaurin or its salt, for example ruboxistaurin mesylate.In some embodiments, the formulation, for example, the gel formulation, is suitable for topical administration.

[0039] In other embodiments, the compound comprises a bisindolylmaleimide or a derivative thereof. In certain embodiments, the bisindolylmaleimide derivative is selected from bisindolylmaleimide I (BIM-1) or bisindolylmaleimide II (BIM-2) or a salt thereof.

[0040] In some embodiments, compound is administered in combination with additional agent, for example, therapeutic agent or cosmetic agent.In some embodiments, one or more additional agents, for example, therapeutic agent, are selected from hydroquinone, tretinoin, corticosteroid, azelaic acid, kojic acid, retinoid, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide, titanium dioxide, cosmetic agent, pigment, fragrance, sunscreen, foaming surfactant, vitamin, hydroxy acid, antioxidant, retinoid or moisturizing agent.

[0041] In some embodiments, one or more additional agents are administered locally. In some embodiments, the additional agent is co-applied with the compound. In some embodiments, the additional agent and the compound are applied to a common area, but at different times. In some embodiments, the additional agent and the compound are included in the same unit dosage form. In some embodiments, the additional agent and the compound are placed in different unit dosage forms. In some embodiments, a second or multiple additional agents are administered. In some embodiments, a second administration of the compound is administered. In some embodiments, a third administration of the compound is administered.

[0042] In some embodiments, it is administered multiple times in 7 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, it is administered multiple times in 14 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, it is administered multiple times in 21 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, the compound is administered multiple times within a 30 day period, e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times.

[0043] In some embodiments, compound is administered every day, every other day, every week or every month.In some embodiments, compound is administered every day for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months or longer.In some embodiments, compound is administered every day for at least 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years or 10 years.

[0044] In some embodiments, the subject has been previously treated with the compound, for example, for at least 1 month, 6 months, 12 months, 24 months, 36 months or 48 months. In some embodiments, the subject has been previously administered one or more doses of the compound, for example, at least 2, 10, 20, 30, 40, 50, 100, 200, 300 or 500 doses of the compound.

[0045] In some embodiments, the method includes applying the compound to a predetermined area of ​​the body, such as a predetermined area of ​​the skin. In some embodiments, the method includes applying the compound to an area of ​​the skin where a hyperpigmentation condition is present. In some embodiments, the method includes applying the compound to an area adjacent to an area of ​​the skin where a hyperpigmentation condition is present. In some embodiments, the method includes applying the compound to the face, arms, back, or other areas where unwanted or otherwise excessive hyperpigmentation is present.

[0046] In some embodiments, a method is provided for reducing pigmentation of growing hair, comprising non-systemically (e.g., topically, intradermally or subcutaneously) applying to the hair-bearing skin of a subject (e.g., at the hair follicle orifice surrounding the growing hair shaft) an effective amount of a compound that selectively inhibits PKCβ, thereby reducing pigmentation of the growing hair (e.g., reducing pigmentation compared to the pigmentation of non-growing hair of the subject).

[0047] In some embodiments, the subject has artificially colored, e.g., dyed, hair.In some embodiments, the compound is administered in a regimen that is effective for reducing the difference in color or tone between the newly growing hair shaft portion and the previous hair shaft portion, e.g., in the subject with artificially colored hair.In some embodiments, the administration of the compound extends the interval, e.g., the period, between applying, e.g., reapplying, artificial coloring, e.g., dye, to hair.In some embodiments, the interval is extended to at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks or 8 weeks.

[0048] In some embodiments, the compound comprises a compound of formula I (e.g., as described herein). In some embodiments, the compound comprises a compound of formula Id (e.g., as described herein). In some embodiments, the compound comprises a compound of formula If-1 (e.g., as described herein). In some embodiments, the compound comprises a compound of formula If-2 (e.g., as described herein). In some embodiments, the compound comprises ruboxistaurin mesylate. In some embodiments, the compound comprises ruboxistaurin. In some embodiments, the compound comprises ruboxistaurin or a salt thereof, e.g., ruboxistaurin mesylate, formulated, e.g., as a gel. In some embodiments, the compound comprises at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, or 1.5% ruboxistaurin or a salt thereof, e.g., ruboxistaurin mesylate, formulated, e.g., as a gel. In some embodiments, the compound is administered topically. In some embodiments, the compound is administered intradermally. In some embodiments, the compound is administered subcutaneously.

[0049] In some embodiments, A compound of formula I (e.g., as described herein); A compound of formula Id (e.g. as described herein); A compound of formula If-1 (e.g., as described herein); A compound of formula If-2 (e.g., as described herein); Ruboxistaurin or a salt thereof; or Ruboxistaurin Mesylate Compounds comprising the compound reduce, e.g., inhibit, melanogenesis, e.g., skin darkening or pigmentation.

[0050] In some embodiments, melanogenesis is induced, for example, by UV exposure, for example, sun exposure or tanning reaction.In some embodiments, the compound reduces or inhibits melanogenesis, for example, skin darkening and pigmentation, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100%.In some embodiments, the reduction, for example inhibition, of melanogenesis is measured by the assay of Example 2.

[0051] In some embodiments, the compound comprises the compound of formula I, the compound of formula Id, the compound of formula If-1, the compound of formula If-2, ruboxistaurin or its salt, such as ruboxistaurin mesylate, formulated as, for example, a gel.In some embodiments, the formulation, such as a gel formulation, comprises at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5% of ruboxistaurin or its salt, such as ruboxistaurin mesylate.In some embodiments, the formulation, such as a gel formulation, is suitable for topical administration.

[0052] In other embodiments, the compound comprises a bisindolylmaleimide or a derivative thereof. In certain embodiments, the bisindolylmaleimide derivative is selected from bisindolylmaleimide I (BIM-1) or bisindolylmaleimide II (BIM-2) or a salt thereof.

[0053] In some embodiments, compound is administered in combination with additional agent, for example, therapeutic agent or cosmetic agent.In some embodiments, one or more additional agents, for example, therapeutic agent, are selected from hydroquinone, tretinoin, corticosteroid, azelaic acid, kojic acid, retinoid, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide, titanium dioxide, cosmetic agent, pigment, fragrance, sunscreen, foaming surfactant, vitamin, hydroxy acid, antioxidant, retinoid or moisturizing agent.

[0054] In some embodiments, one or more additional agents are administered locally. In some embodiments, the additional agent is co-applied with the compound. In some embodiments, the additional agent and the compound are applied to a common area, but at different times. In some embodiments, the additional agent and the compound are included in the same unit dosage form. In some embodiments, the additional agent and the compound are placed in different unit dosage forms. In some embodiments, a second or multiple additional agents are administered. In some embodiments, a second administration of the compound is administered. In some embodiments, a third administration of the compound is administered.

[0055] In some embodiments, it is administered multiple times in 7 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, it is administered multiple times in 14 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, it is administered multiple times in 21 days, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. In some embodiments, the compound is administered multiple times within a 30 day period, e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times.

[0056] In some embodiments, compound is administered every day, every other day, every week or every month.In some embodiments, compound is administered every day for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months or longer.In some embodiments, compound is administered every day for at least 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years or 10 years.

[0057] In some embodiments, the subject has been previously treated with the compound, for example, for at least 1 month, 6 months, 12 months, 24 months, 36 months or 48 months. In some embodiments, the subject has been previously administered one or more doses of the compound, for example, at least 2, 10, 20, 30, 40, 50, 100, 200, 300 or 500 doses of the compound.

[0058] In some embodiments, the method includes applying the compound to a predetermined area of ​​the body, such as a predetermined area of ​​the skin. In some embodiments, the method includes applying the compound to an area of ​​the skin where a hyperpigmentation condition is present. In some embodiments, the method includes applying the compound to an area adjacent to an area of ​​the skin where a hyperpigmentation condition is present. In some embodiments, the method includes applying the compound to the face, arms, back, or other areas where unwanted or otherwise excessive hyperpigmentation is present.

[0059] In one embodiment, A compound of formula I (e.g., as described herein); A compound of formula Id (e.g. as described herein); A compound of formula If-1 (e.g., as described herein); A compound of formula If-2 (e.g., as described herein); Ruboxistaurin or a salt thereof; or Ruboxistaurin Mesylate Provided herein is a unit dosage form or formulation comprising a compound comprising: wherein the compound in the unit dosage form or formulation is in an amount sufficient to reduce, e.g., inhibit, melanogenesis, e.g., skin darkening or pigmentation. In some embodiments, the compound in the unit dosage form or formulation, e.g., gel formulation, is present in a dose of at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, or 1.5% of the compound of formula I, the compound of formula Id, the compound of formula If-1, the compound of formula If-2, ruboxistaurin or a salt thereof, e.g., ruboxistaurin mesylate. In some embodiments, the unit dosage form or formulation, e.g., a gel formulation, comprises ruboxistaurin or a salt thereof, e.g., ruboxistaurin mesylate, in a dosage of at least 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, or 1.5%. In some embodiments, the unit dosage form or formulation, e.g., a gel formulation, of any of the compounds of Formula I, Formula Id, Formula If-1, Formula If-2, ruboxistaurin or a salt thereof, e.g., ruboxistaurin mesylate, is suitable for topical administration.

[0060] In some embodiments, melanogenesis is induced, for example, by UV exposure, for example, sun exposure or sunburn reaction.In some embodiments, the compound reduces, for example inhibits, melanogenesis, for example, skin darkening and pigmentation, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100%.In some embodiments, the reduction, for example inhibition, of melanogenesis is measured by the assay of Example 2.

[0061] In some embodiments, a unit dosage form is provided, comprising a first unit dosage form that comprises an effective amount of a compound that selectively inhibits PKCβ, and is formulated for non-systemic administration; and a second unit dosage form that comprises an effective amount of an additional agent, such as a therapeutic or cosmetic agent.In some embodiments, the additional agent comprises an agent selected from hydroquinone, tretinoin, corticosteroids, azelaic acid, kojic acid, retinoids, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide, titanium dioxide, cosmetic agents, pigments, fragrances, sunscreens, foaming surfactants, vitamins, hydroxy acids, antioxidants, retinoids or moisturizers.

[0062] In some embodiments, the present invention provides pharmaceutical compositions for use in the methods described herein. In some embodiments, the pharmaceutical compositions are formulated as lotions, creams, serums, sprays, mousses, aerosols, emulsions, cakes, ointments, gels, pastes, patches, pencils, wipes, masks, sticks, foams, elixirs, or concentrates. In some embodiments, the pharmaceutical composition further comprises one or more additional agents, e.g., a therapeutic agent, selected from hydroquinone, tretinoin, corticosteroids, azelaic acid, kojic acid, retinoids, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylate, ecamsule, zinc oxide, titanium dioxide, cosmetic agents, dyes, fragrances, sunscreens, foaming surfactants, vitamins, hydroxy acids, antioxidants, retinoids, or moisturizers.

[0063] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the invention belongs.Methods and materials similar or equivalent to those described herein can be used in the practice and testing of the present invention, and suitable methods and materials are described below.All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety.In case of conflict, the present specification, including definitions, will control.In addition, the materials, methods and examples are for illustrative purposes only and are not intended to be limiting.

[0064] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims. [Brief description of the drawings]

[0065] [Figure 1] Photomicrographs of awl and zig-zag hairs harvested from dorsal mouse skin. Eight- to nine-week-old mice were waxed to completely remove hair and stimulate follicles for a new cycle of hair growth and then treated with vehicle (DMSO:PG) alone (A), 4% HQ (B), the nonselective PKC inhibitor bisindolylmaleimide (Bis) (C), or the highly selective PKCβ inhibitor ruboxistaurin (D). Twenty-one days after depilation, all hair-treated groups appeared lighter in color compared to the control group (A). Zig-zag hairs (those with the most hair shaft type and more surface follicles (located in the mid-dermis)) from groups treated with both Bis and ruboxistaurin were lightest in color.

[0066] [Diagram 2]Bar graph showing the effect of topically applied compounds on hair pigmentation density (reflecting the amount of melanin produced in follicular melanocytes and transferred to follicular keratinocytes that subsequently differentiate to form the hair shaft). The average shade value in the hair shaft was determined using ImageJ (NIH) software. The shade value is the sum of the shade values ​​of all pixels in the hair shaft divided by the number of pixels; values ​​range from 0 (white, no pigment) to 255 (black). Small hairs (B) show significantly higher lightening effect than large hairs (A) in all treatment groups. The median shade value of small hairs is indicated by the red line. Student's t-test (*<0.05; **<0.01). (Rubo=ruboxistaurin)

[0067] [Diagram 3] Bar graph showing the maximum lightening effect of compounds applied topically to small hairs. Dark and light hairs were selected for separate analysis based on the median shade value of the main group of small hairs. Hairs with values ​​higher and lower than the median were considered dark (A) and light (B), respectively. Student's t-test (*<0.05; **<0.01; ***<0.001). (Rubo=ruboxistaurin)

[0068] [Figure 4] Graph showing Investigator Dynamic Grading Assessment (IDGA) results of test areas in subjects treated with ruboxistaurin gel or placebo. Three doses of ruboxistaurin gel formulated as a gel (0.1%, 0.5% or 1.0%) were administered. The y-axis shows the IDGA score (shown in Table 2). The average value for all test sites from all subjects is plotted with error bars indicating standard deviation. (Rubox = ruboxistaurin) DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0069] Detailed Description of the Invention The protein kinase C (PKC) family of proteins is a group of serine / threonine kinases that includes at least 11 different isoforms, including, for example, PKCα, PKCβ (PKCβ1 and PKCβ2), PKCγ, PKCδ, PKCε, PKCζ, PKCι, PKCθ, and PKCη. Both PKCβ and PKCα are expressed in skin; however, PKCβ is only expressed in melanocytes; whereas PKCα is expressed in melanocytes, keratinocytes, and fibroblasts. Skin hyperpigmentation disorders are characterized by a global or localized increase in melanin (increase compared to an individual's normal or average skin pigmentation), producing increased pigment (increase compared to an individual's normal or average skin pigmentation) in one or more areas of the skin. Tyrosinase mediates the first and rate-limiting step in melanin biosynthesis and is activated by phosphorylation by PKCβ.

[0070] The present invention provides novel methods for treating hyperpigmentation conditions using local or non-systemic (e.g., topical, intradermal, subcutaneous) administration of selective PKCβ inhibitors (e.g., compounds described herein, such as compounds of Formula I, compounds of Formula II, or ruboxistaurin). While non-selective PKC inhibitors, bisindolylmaleimides (Bis), have been described in the literature (e.g., Park et al. (2004) J of Investigative Dermatology 122: 159-166; and U.S. Pat. No. 5,962,417), the compounds of the present invention are selective PKCβ inhibitors (e.g., compounds described herein, such as compounds of Formula I, compounds of Formula II, or ruboxistaurin). Bis inhibits the activity of several PKC isoforms, e.g., Bis inhibits the PKCβ IC 50 = 18nM; PKCα IC 50 = 8.4 nM; and PKCζ IC 50=5.8 μM) (Toullec, D. et al. 1991. J. Biol. Chem. 266: 15771-15781. PMID: 1874734; Martiny-Baron, G. et al. 1993. J. Biol. Chem. 268: 9194-9197. PMID: 8486620; Kiss, Z. et al. 1995. Biochim. Biophys. Acta. 1265: 93-95. PMID: 7857990; Zhou, T. et al. 1999. Nat. Med. 5: 42-48. PMID: 9883838, the contents of each of which are incorporated herein by reference). In contrast, ruboxistaurin is a selective and potent inhibitor of PKCβ1 and PKCβ2 (IC 50 = 4.7 and 5.9 nM) for the other PKC isoforms α, γ, δ, ε, ζ, and η. 50 The values ​​are 360 ​​nM, 300 nM, 250 nM, 600 nM, >100,000 nM, and 52 nM, respectively. (Jirousek, MR, Gillig, JR, Gonzalez, CM, et al. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase Cβ. J Med Chem 39 2664-2671 (1996), the contents of each of which are incorporated herein by reference.)

[0071] Non-selective PKCβ inhibitors such as Bis may result in side effects due to inhibition of other PKC isoforms. Several PKC isoforms, such as eta, delta and alpha, are believed to play a role in regulating keratinocyte proliferation and differentiation (e.g. Denning MF et al., Cell Growth Differ. 1995: 6(2):149-57; Kashiwagi M et al., Biochem. 2002 Dec; 132(6): 853-7; Seo H et al., Experimental & Molecular Medicine (2004) 36, 292-299; doi:10.1038 / emm.2004.40; Bollag W et al., Journal of Investigative Dermatology (2009) 129, 2330-2332. doi:10.1038 / jid.2009.165; Cabodi S et al., Molecular Cell, Volume 6, Issue 5, November 2000, Pages 1121-1129). Thus, non-selective PKC inhibitors such as Bis may have off-target effects, including possible effects on keratinocyte proliferation, differentiation and behavior.

[0072] An exemplary compound for use in the methods described herein is ruboxistaurin (see also U.S. Pat. No. 5,710,145 and U.S. Pat. No. 5,559,228, the contents of each of which are incorporated herein by reference). Ruboxistaurin has a molecular weight of 468.546 g / mol, which is a relatively large compound for local or non-systemic administration (e.g., topical administration), since compounds with a molecular weight of about 500 g / mol or more are generally considered incompatible with local delivery (Bos JD et al. (2000) Exp Dermatol. 9(3):165-9). Furthermore, ruboxistaurin is poorly soluble and bright orange in color, adding additional challenges to the topical administration of the compound.

[0073] definition As used herein, "hyperpigmentation condition" or "hyperpigmentation disorder" or "hyperpigmentation disease" refers to a condition characterized by a generalized or localized increase in an individual's normal skin color. Skin hyperpigmentation disorders include, for example, melasma, postinflammatory hyperpigmentation, discoid lupus erythematosus, and other forms of increased epidermal melanin deposition. Hyperpigmentation conditions can also include conditions in which pigmentation of one or more areas of the skin is unwanted or otherwise characterized as excessive coloring. Hyperpigmentation conditions include hyperpigmentation conditions mediated by melanin deposition.

[0074] As used herein, "selective PKCβ inhibitor" refers to a compound specific to PCK isoform β (PKCβ1 and / or PKCβ2). A selective PKCβ inhibitor has high specificity for PKCβ compared to at least one other PKC isoform. In some embodiments, a selective PKCβ inhibitor has high specificity for PKCβ compared to two or more other PKC isoforms (e.g., PCKα, PKCγ). In some embodiments, a selective PKCβ inhibitor has high specificity for PKCβ compared to PKCα, PKCγ, PKCδ, PKCε, PKCζ, PKCι, PKCθ and PKCη. A selective PKCβ inhibitor can inhibit the activity of other non-PCKβ isoforms (e.g., PCKα); however, the inhibitory activity for non-PKCβ isoforms is absolutely and relatively higher than the compound inhibitory activity for PKCβ (PKCβ1 and / or PKCβ2).

[0075] As used herein, "non-systemic" refers to a route of administration other than introduction into the circulatory system. Non-systemic administration may result in the administered drug being in the circulatory system, but administration is outside of the circulatory system.

[0076] As used herein, the terms "patient," "subject," "individual," and "host" refer to a human or non-human animal having or suspected of having a hyperpigmentation condition (e.g., a selective PKCβ-inhibitor responsive hyperpigmentation condition or a PKCβ-mediated hyperpigmentation condition, e.g., melasma). In some embodiments, the subject is a human. In some embodiments, the subject is a mammal. In some embodiments, the subject is a mammal other than a rodent.

[0077] As used herein, "treat" and "treating" a condition or disease as described herein, e.g., a hyperpigmentation condition (e.g., a selective PKCβ-inhibitor responsive hyperpigmentation condition or a PKCβ-mediated hyperpigmentation condition, e.g., melasma), refers to the reduction or amelioration of the progression, severity and / or duration of the condition or one or more of its symptoms.

[0078] The term "therapeutic effect" refers to a beneficial local or systemic effect in animals, particularly mammals, and more particularly humans, resulting from administration of a compound or composition described herein. The phrase "therapeutically effective amount" or "effective amount" refers to an amount of a compound or composition described herein that is effective to treat a hyperpigmentation condition (e.g., a selective PKCβ-inhibitor responsive hyperpigmentation condition or a PKCβ-mediated hyperpigmentation condition, such as melasma) with a reasonable benefit / risk ratio. The therapeutically effective amount of such a substance varies depending on the subject and disease condition being treated, the size and skin condition of the lesion, the age of the subject, the severity of the disease condition, the method of administration, etc., which can be easily determined by one skilled in the art.

[0079] The term "predetermined skin area" as used herein refers to an area of ​​the skin of a subject, for example, an area of ​​healthy skin, or an area of ​​skin having a condition described herein, for example, a hyperpigmentation condition (e.g., melasma) or an unwanted hyperpigmentation condition described herein. In some embodiments, the predetermined skin area is selected, for example, selected or identified, for example, based on measuring the amount of color, for example, erythema or pigmentation, of the skin area. In some embodiments, the predetermined skin area is selected, for example, selected or identified, for example, based on measuring the erythema or pigmentation in an area adjacent to the skin area. The amount of color in the skin can be measured, for example, by a colorimeter, and grading, for example, as described herein. In some embodiments, Individual Typology Angle (ITA) is used to grade the amount of color in the skin, as described herein. In other embodiments, Investigator Dynamic Grading Assessment (IDGA) is used to grade the amount of color in the skin, as described herein.

[0080] Selective PKC-β inhibitors The present invention relates to a PKC-β inhibitor for use in treating a disease or disorder (e.g., a hyperpigmentation condition) described herein. In some embodiments, the PKC-β inhibitor comprises a bisindolylmaleimide, a phthalimide, or a derivative thereof. In some embodiments, the PKC-β inhibitor is represented by formula (I): [ka] [During the ceremony, W is -O-, -S-, -S(O)-, -S(O) 2 -, -C(O)-, C 2 -C 6 Alkylene, substituted alkylene, C 2 -C 6 Alkenylene, substituted alkenylene, aryl, aryl(CH 2 ) m O, heterocyclyl, heterocyclyl(CH2 ) m O, -NR 3 -, -N(O)R 3 -, -C(O)NH- or -NHC(O)-; Each of X and Y is independently C 1 -C 4 alkylene, substituted alkylene, or X, Y and W combine to form -(CH 2 ) n -AA-formation; Each R 1 are independently hydrogen, halo, C 1 -C 4 Alkyl, Hydroxyl, C 1 -C 4 Alkoxy, C 1 -C 4 Haloalkyl, Nitro, -NR 4 R 5 , or -NHC(O)(C 1 -C 4 alkyl); R 2 is hydrogen, -CH 3 C(O), -NH 2 or hydroxyl; R 3 is hydrogen, (CH 2 ) m Aryl, C 1 -C 4 Alkyl, -C(O)O(C 1 -C 4 alkyl), -C(O)NR 4 R 5 , -(C=NH)NH 2 , -S(O)(C 1 -C 4 alkyl), -S(O) 2 (NR 4 R 5 ) or -S(O) 2 (C 1 -C 4 alkyl); Each R 4 and R 5 are independently hydrogen, C 1 -C 4 alkyl, phenyl, benzyl, or R 4and R 5 form together with the nitrogen to which they are attached a saturated or unsaturated five- or six-membered ring; AA is an amino acid residue; each m is independently 0, 1, 2, or 3; and n is independently 2, 3, 4 or 5. or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0081] In some embodiments, XWY comprises 4 to 30 atoms, which may be further substituted or unsubstituted. In some embodiments, XWY comprises 5 atoms, 6 atoms, 7 atoms, 8 atoms, 9 atoms, 10 atoms, 11 atoms, 12 atoms, 13 atoms, 14 atoms, 15 atoms, 16 atoms, 17 atoms, 18 atoms, 19 atoms, 20 atoms, 21 atoms, 22 atoms, 23 atoms, 24 atoms, 25 atoms, 26 atoms, 27 atoms, 28 atoms, 29 atoms, or 30 atoms, which may be further substituted or unsubstituted. In some embodiments, XWY comprises 10 to 30 atoms, which may be further substituted or unsubstituted. In some embodiments, XWY comprises 20 to 30 atoms, which may be further substituted or unsubstituted.

[0082] In some embodiments, R 1 and R 2 is independently hydrogen. In some embodiments, each of X and Y is independently alkylene or substituted alkylene. In some embodiments, W is substituted alkylene, -O-, -S-, -C(O)NH-, -NHC(O)-, or NR 3 In some embodiments, R 1 and R 2 is independently hydrogen; each of X and Y is independently alkylene or substituted alkylene; W is substituted alkylene, -O-, -S-, -C(O)NH-, -NHC(O)-, or NR3 It is.

[0083] In some embodiments, the compound of Formula (I) has the formula (Ia): [ka] [During the ceremony, Z is -(CH 2 ) p -or-(CH 2 ) p -O-(CH 2 ) p and; R 6 is hydroxyl, -SH, C 1 -C 4 Alkyl, (CH 2 ) m Aryl, -NH(aryl), N(CH 3 )(CF 3 ), NH(CF 3 ) or -NR 4 R 5 and; R 4 is hydrogen or C 1 -C 4 is alkyl; R 5 is hydrogen, C 1 -C 4 is alkyl or benzyl; p is 0, 1, or 2; and each m is independently 2 or 3; or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0084] In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, Z is CH 2 In some embodiments, R 6 NH 2 , NH(CF 3 ) or N(CH 3 ) 2 In some embodiments, Z is CH 2 and R6 NH 2 , NH(CF 3 ) or N(CH 3 ) 2 In some embodiments, m is 2 and Z is CH 2 and R 6 NH 2 , NH(CF 3 ) or N(CH 3 ) 2 It is.

[0085] In another embodiment, the compound of formula (I) has formula (Ib): [ka] [During the ceremony, Z is -(CH 2 ) p - and; R 6 is N(CH 3 )(CF 3 ), NH(CF 3 ) or -NR 4 R 5 and; R 4 and R 5 each independently represents hydrogen or C 1 -C 4 is alkyl; R 5 is hydrogen, C 1 -C 4 is alkyl or benzyl; p is 0, 1, or 2; and each m is independently 2 or 3; or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0086] In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, p is 1 or 2. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, R 6 -NR 4 R5 and R 4 and R 5 Each of the following may be independently 1 -C 4 Alkyl (e.g. CH 3 In some embodiments, R 6 is N(CH 3 ) 2 In some embodiments, m is 2 and p is 1. In some embodiments, m is 2, p is 1, and R 6 is N(CH 3 ) 2 It is.

[0087] In other embodiments, the compound of formula (I) has the formula (Ic): [ka] [During the ceremony, R 6 is N(CH 3 )(CF 3 ), NH(CF 3 ) or -NR 4 R 5 is or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0088] In some embodiments, R 6 -NR 4 R 5 and R 4 and R 5 Each of the following may be independently 1 -C 4 Alkyl (e.g. CH 3 In some embodiments, R 6 is N(CH 3 ) 2 It is.

[0089] In other embodiments, the compound of formula (I) has the formula (Id): [ka] or a pharmaceutically acceptable salt, stereoisomer, racemate or solvate thereof. In some embodiments, the compound of formula (Id) is 9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,2,13]oxadiazacyclohexadecin-18,20-dione, such as ruboxistaurin, or a pharmaceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0090] In other embodiments, the compound of formula (I) has the formula (Ie): [ka] [During the ceremony, A is N(CH 3 ) 2 is the counter ion of the moiety or a pharmaceutically acceptable salt, stereoisomer, racemate or solvate thereof.In some embodiments, the compound of formula (Ie) is 9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,2,13]oxadiazacyclohexadecin-18,20-dione salt, such as ruboxistaurin salt, or a pharmaceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0091] In some embodiments, A is acetic acid, benzoic acid, bromine, carbonic acid, chlorine, citric acid, fluorine, fumaric acid, gluconic acid, hydrochloric acid, hydrobromic acid, hydrofluoric acid, iodine, lactic acid, phosphonic acid, phosphoric acid, methanesulfonic acid, sulfonic acid, tartaric acid or its salt.In some embodiments, A is acetic acid, benzoic acid, citric acid, hydrochloric acid, hydrobromic acid, hydrofluoric acid, methanesulfonic acid, tartaric acid or its salt.In some embodiments, A is methanesulfonic acid or its salt.

[0092] In other embodiments, the compound of formula (I) has the formula (If): [ka] or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0093] In some embodiments, the PKC-β inhibitor (e.g., a compound of Formula (If)) is 9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,2,13]oxadiazacyclohexadecin-18,20-dione mesylate, e.g., ruboxistaurin mesylate, or a pharmaceutically acceptable salt, stereoisomer, racemate, or solvate thereof.

[0094] The compound of formula (I) (e.g., the compound of formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie) or formula (If)) can exist as a solvate, for example, a solvate with water (i.e., hydrate), methanol, ethanol, dimethylformamide, ethyl acetate, etc. Mixtures of solvates can also be produced. The source of the solvate can come from a solvent during the synthesis of the compound, for example, in the purification (e.g., crystallization) or in preparation for purification (e.g., crystallization), or from a solvent associated with such a solvent. In some embodiments, the compound of formula (I) (e.g., the compound of formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie) or formula (If)) exists as a monohydrate or trihydrate.

[0095] In some embodiments, the PKC-β inhibitor of formula (I) can be a stereoisomer or racemate of the compound of formula (I). In certain embodiments, the PKC-β inhibitor of formula (If) is represented by formula (If-1) or formula (If-2): [ka] or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof. In some embodiments, the PKC-β inhibitor (e.g., a compound of formula (I)) is (9S)-9[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,2,13]oxadiazacyclohexadecin-18,20-dione mesylate (e.g., formula (If-1)) or (9R)-9[ (dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,2,13]oxadiazacyclohexadecin-18,20-dione mesylate (e.g., of formula (If-2)), such as ruboxistaurin mesylate or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0096] Preparation of compounds of formula (I) (e.g., compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If)) may be achieved by the methods described in U.S. Patent Nos. 5,552,396 and 6,015,807, which are incorporated herein by reference in their entireties. However, preparation of compounds of formula (I) (e.g., compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If)) may be achieved by other protocols or methods known to those of skill in the art.

[0097] In some embodiments, the PKC-β inhibitor has formula (II): [ka] [During the ceremony, Each R 1 are independently hydrogen, halo, C 1 -C 4 Alkyl, Hydroxyl, C 1 -C 4 Alkoxy, haloalkyl, nitro, NR 4 R 5 or -NHC(O)(C 1 -C 4alkyl); R 2 is hydrogen, -CH 3 C(O), -NH 2 or hydroxyl; Each R 4 and R 5 are independently hydrogen, C 1 -C 4 alkyl, phenyl, benzyl, or R 4 and R 5 form together with the nitrogen to which they are attached a saturated or unsaturated five- or six-membered ring; R 7 is hydrogen or C 1 -C 4 is alkyl; R 8 Each R is 1 or more. 9 substituted by cycloalkyl or heterocyclyl; R 9 Each of these may be 1 or more R 10 C optionally substituted by 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, C 1 -C 4 haloalkyl, halo, cyano, nitro, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; Each R 10 is halo, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, C 1 -C 4 haloalkyl, cyano, or nitro; and each m is independently 0, 1, 2, or 3; or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0098] In some embodiments, each m is 0.

[0099] In some embodiments, R2 is hydrogen.

[0100] In some embodiments, R 7 is C 1 -C 4 In some embodiments, R 7 is methyl.

[0101] In some embodiments, R 8 is heterocyclyl. In some embodiments, R 8 is nitrogen-containing heterocyclyl. In some embodiments, R 8 is a 6-membered nitrogen-containing heterocyclyl. In some embodiments, R 8 is piperidinyl (e.g. 1,4-piperidinyl).

[0102] In some embodiments, R 9 is heteroarylalkyl. In some embodiments, R 9 where n is 1, 2, 3, or 4 (CH 2 ) n -pyridyl. In some embodiments, R 9 (CH 2 )-pyridyl. In some embodiments, R 9 is 2-(CH 2 )-pyridyl.

[0103] In some embodiments, the compound of Formula (II) has the formula (IIa): [ka] [During the ceremony, R 2 is hydrogen, -CH 3 C(O), -NH 2 or hydroxyl; R 7 is hydrogen or C 1 -C 4 is alkyl; R 9 is C1 -C 4 Alkyl, C 1 -C 4 Alkoxy, C 1 -C 4 haloalkyl, halo, cyano, or nitro; R 9a In some cases, R is 1 or more 10 aryl, arylalkyl, heteroaryl or heteroarylalkyl, optionally substituted with; and Each R 10 Independently, Halo, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, C 1 -C 4 haloalkyl, cyano or nitro. or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0104] In some embodiments, each m is 0.

[0105] In some embodiments, R 2 is hydrogen.

[0106] In some embodiments, R 7 is C 1 -C 4 In some embodiments, R 7 is methyl.

[0107] In some embodiments, R 9a is heteroarylalkyl. In some embodiments, R 9a where n is 1, 2, 3 or 4 (CH 2 ) n -pyridyl. In some embodiments, R 9a (CH 2 )-pyridyl. In some embodiments, R 9a is 2-(CH 2 )-pyridyl.

[0108] In some embodiments, the compound of Formula (II) has the formula (IIb): [ka] [During the ceremony, R 9a In some cases, R is 1 or more 10 aryl, arylalkyl, heteroaryl or heteroarylalkyl optionally substituted with; Each R 10 Independently, Halo, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, C 1 -C 4 haloalkyl, cyano or nitro. or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0109] In some embodiments, R 9a is heteroarylalkyl. In some embodiments, R 9a where n is 1, 2, 3, or 4 (CH 2 ) n -pyridyl. In some embodiments, R 9a (CH 2 )-pyridyl. In some embodiments, R 9a is 2-(CH 2 )-pyridyl.

[0110] In some embodiments, the PKC-β inhibitor of formula (II) has the formula (IIc): [ka] or a pharmaceutically acceptable salt, stereoisomer, racemate or solvate thereof. In some embodiments, the PKC-β inhibitor (e.g., a compound of formula (II)) is 3-(1-methyl-1H-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)piperidin-4-yl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione (e.g., formula (IIc)), such as LY-317615 or enzastaurin, or a pharmaceutically acceptable salt, stereoisomer, racemate or solvate thereof. In some embodiments, the PKC-β inhibitor (e.g., a compound of formula (II)) is enzastaurin hydrochloride.

[0111] In some embodiments, the PKC-β inhibitor has formula (III): [ka] [During the ceremony, X 1 and X 2 each independently represents -O-, -NR 4 -or-S-; A 1 and A 2 each independently represents one or more of 9 is an aryl or heteroaryl optionally substituted with R 2 is hydrogen, -CH 3 C(O), -NH 2 or hydroxyl; R 4 is hydrogen or C 1 -C 4 is alkyl; and R 9 is C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, C 1 -C 4 haloalkyl, halo, cyano or nitro. or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0112] In some embodiments, X 1 and X 2 One of them is independently -NR 4 In some embodiments, X 1 and X 2 each independently represents -NR 4 In some embodiments, X 1 and X 2 Each of is independently -NH-.

[0113] In some embodiments, A 1 and A 2 is independently aryl. 1 and A 2 Each of A is independently aryl. 1 and A 2 Each of A is independently phenyl. 1 and A 2 Each of the groups independently represents one R 9 In some embodiments, A is phenyl substituted with 1 and A 2 Each of the following is the first round of the para-ranking. 9 In some embodiments, R 9 is halo (e.g., fluoro).

[0114] In some embodiments, the PKC-β inhibitor has formula (IIIa): [ka] [During the ceremony, X 1 and X 2 each independently represents -O-, -NR 4 -or-S-; R 2 is hydrogen, -CH 3 C(O), -NH 2 or hydroxyl; R4 is hydrogen or C 1 -C 4 is alkyl; and R 9a and R 9b Each of the C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, C 1 -C 4 haloalkyl, halo, cyano or nitro. or a pharma- ceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0115] In some embodiments, X 1 and X 2 One of them is independently -NR 4 In some embodiments, X 1 and X 2 each independently represents -NR 4 In some embodiments, X 1 and X 2 Each of is independently -NH-.

[0116] In some embodiments, each phenyl ring is one R 9a and one R 9b In some embodiments, each phenyl ring is substituted with one R 9a and one R 9b In some embodiments, R 9a and R 9b In some embodiments, one of R 9a and R 9b Each of is halo (eg, fluoro).

[0117] In some embodiments, the PKC-β inhibitor of formula (III) has the formula (IIIb): [ka] or a pharmaceutically acceptable salt, stereoisomer, racemate or solvate thereof. In some embodiments, the PKC-β inhibitor (e.g., a compound of formula (III)) is 5,6-bis(4-fluorophenoxy)isoindoline-1,3-dione (e.g., formula (IIIb)), e.g., CGP 53353, CG 53353, or a pharmaceutically acceptable salt, stereoisomer, racemate or solvate thereof.

[0118] Other PKCβ inhibitors described herein include, for example, PKCβ pseudosubstrates described in Park et al. (1999) Protein Kinase C-β Activates Tyrosinase by Phosphorylating Serine Residues in Its Cytoplasmic Domain. JBC Vol. 274, No. 23, Issue of June 4, pp. 16470-16478; and Park et al. (2004) The receptor for activated C-kinase-I (RACK-I) anchors activated PKC-β on melanosomes. Journal of Cell Science 117 (16) p. 3659. Exemplary PKCβ pseudosubstrates include, for example, amino acids comprising, consisting essentially of, the amino acid sequence Glu-Asp-Tyr-His-Ser-Leu-Tyr-Gln-Ser-His-Leu (SEQ ID NO:1); and amino acids consisting of the amino acid sequence Glu-Asp-Tyr-His-Ser-Leu-Tyr-Gln-Ser-His-Leu (SEQ ID NO:1). PKCβ pseudosubstrates having at least 75%, 80%, 85%, 90%, 95%, 99% homology to SEQ ID NO:1 are also contemplated.

[0119] chemical definition Definitions of certain functional groups and chemical terms are described in more detail below. Chemical elements are listed in the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th In addition, general principles of organic chemistry, as well as specific functional moieties and reactivities, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5 th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987.

[0120] Unless otherwise specified, structures depicted herein are also intended to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Thus, single stereoisomeric isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise specified, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise specified, structures depicted herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, the replacement of hydrogen by deuterium or tritium or 13 C or 14Compounds having this structure including the replacement of a carbon with a C-rich carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or as therapeutic agents according to the present invention.

[0121] In some embodiments, when a particular enantiomer is preferred, it can be provided substantially free of the corresponding enantiomer and can also be referred to as "optically-enriched". As used herein, "optically-enriched" means that a compound is produced that has a significantly higher proportion of one enantiomer. In certain embodiments, the compound is produced with at least about 90% by weight of the preferred enantiomer. In other embodiments, the compound is produced with at least 95%, 98%, 99% or 99.9% by weight of the preferred enantiomer. The preferred enantiomer can be isolated from the racemic mixture by any method known to those skilled in the art, including chiral high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts, or produced by asymmetric synthesis. See, e.g., Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, et al., Tetrahedron 33:2725 (1977); Eliel, EL Stereochemistry of Carbon Compounds (McGraw Hill, NY, 1962); Wilen, SH Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

[0122] As used herein, the term "alkyl" refers to any group having a C 1 -C 10 Alkyl, C 1 -C 6 Alkyl and C 1-C 4 It represents a saturated cyclic, straight chain or branched hydrocarbon, such as a straight chain or branched 1 to 10, 1 to 16, or 1 to 4 carbon atom group, respectively, referred to as alkyl. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec-hexyl, and the like.

[0123] The term "alkylene" as used herein refers to a divalent alkyl group. Typical alkylene groups are methylene, ethylene, propylene, trimethylene, and the like.

[0124] As used herein, the terms "alkenyl" and "alkynyl" are art-recognized and refer to unsaturated aliphatic groups analogous in chain length and possible substitution to the alkyls described above, but which contain at least one double or triple bond, respectively. Exemplary alkenyl groups include, but are not limited to, -CH=CH 2 and -CH 2 CH=CH 2 The terms "alkenylene" and "alkynylene" refer to divalent alkenyl and alkynyl groups, respectively.

[0125] As used herein, the term "alkoxy" refers to a straight or branched alkoxy group having 1 to 6 carbon atoms (e.g., C 1 -C 6 Alkyl-O-) (i.e., C 1 -C 6 Examples of alkoxy groups include, but are not limited to, groups such as methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, tert-butyloxy, pentyloxy or hexyloxy.

[0126] The term "aryl" as used herein refers to a monocyclic, bicyclic or polycyclic hydrocarbon ring system in which at least one ring is aromatic. Representative aryl groups include entirely aromatic ring systems such as phenyl, naphthyl and anthracenyl, as well as ring systems in which an aromatic carbocyclic ring is fused with one or more non-aromatic carbons, such as indanyl, phthalimidyl, naphthomimidyl or tetrahydronaphthyl.

[0127] As used herein, the term "cycloalkyl" refers to a monocyclic or fused, spiro-fused and / or bridged bicyclic or polycyclic hydrocarbon ring system in which each ring is fully saturated or contains one or more units of unsaturation, but no aromatic rings are present. Representative cycloalkyl groups include cyclopentyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0128] The terms "halo" and "halogen" as used herein refer to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br) or iodine (iodo, -I).

[0129] As used herein, the term "haloalkyl" refers to an alkyl group substituted with one or more halogen groups, e.g., CF 3 Refers to...

[0130] As used herein, the terms "hydroxyl" and "hydroxyl" refer to an --OH group.

[0131] The term "heteroaryl" as used herein refers to a monocyclic, bicyclic or polycyclic ring system in which at least one ring is aromatic and contains a heteroatom; the other rings are not heterocyclyl. Representative heteroaryls include (i) each ring contains a heteroatom and is aromatic, such as imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, indolizinyl, purinyl, naphthyridinyl and pteridinyl; (ii) each ring is aromatic or cycloalkyl, at least one aromatic ring contains a heteroatom and at least one other ring is a hydrocarbon ring, or (iii) each ring is aromatic or cycloalkyl, such as indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, ... (iii) each ring is aromatic or cycloalkyl, and at least one aromatic ring shares a bridgehead heteroatom with other aromatic ring, for example, 4H-quinolizinyl.In certain embodiments, heteroaryl is a monocyclic or bicyclic ring that contains 5 or 6 ring atoms, and 1, 2, 3 or 4 ring atoms are independently selected from N, O and S.

[0132] The terms "arylalkyl" and "heteroarylalkyl" as used herein refer to an (aryl)alkyl group or a (heteroaryl)alkyl group, respectively, where aryl and heteroaryl are as described herein.

[0133] As used herein, the term "heterocyclyl" refers to monocyclic or fused, spiro-fused and / or bridged bicyclic and polycyclic ring systems in which at least one ring is saturated or partially unsaturated (but not aromatic) and contains a heteroatom. Representative heterocyclyls include (i) all rings are non-aromatic and at least one ring contains a heteroatom, such as tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl and quinuclidinyl; (ii) at least one ring is non-aromatic and contains a heteroatom, such as tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidinyl, piperidinyl, pyrrolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl and quinuclidinyl; (iii) ring systems in which at least one ring is non-aromatic and contains a heteroatom and at least one other ring is aromatic and contains a heteroatom, such as 3,4-dihydro-1H-pyrano[4,3-c]pyridine and 1,2,3,4-tetrahydro-2,6-naphthyridine. In certain embodiments, the heterocyclyl is a monocyclic or bicyclic ring, each of which contains 3 to 7 ring atoms, with one, two, three, or four of the ring atoms being independently selected from N, O, and S.

[0134] As used herein, the term "nitro" refers to -NO 2 Refers to the base.

[0135] The compounds of the invention described herein may contain "substituted" moieties. In general, the term "substituted", whether preceded by the term "optionally" or not, means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. Unless otherwise specified, a "substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituents may be the same or different at each position. In a broad aspect, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclyl and heterocyclyl, aromatic and nonaromatic substituents of organic compounds (e.g., alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl or heteroaryl, any of which may themselves be further substituted), as well as halogen, carbonyl (e.g., aldehyde, ketone, ester, carboxyl or formyl), thiocarbonyl (e.g., thioester, thiocarboxylate, or thioformate), amino, -N(R b )(R c ) (where each R b and R c are independently H or C 1 -C 6 Alkyl, cyano, nitro, -SO 2 N(R b )(R c ), -SOR d and S(O) 2 R d (Here, each R b , R c and R d are independently H or C 1 -C 6 Exemplary substituents include, for example, those listed above.

[0136] Permissible substituents can be one or more and the same or different for appropriate organic compounds. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds. It is further understood that "substituted" or "substituted" includes the proviso that such substituents are in accordance with the atom to be substituted and the permissible valence of the substituent, and that the substitution results in a stable compound that does not spontaneously undergo transformation, for example, by rearrangement, cyclization, elimination, and the like.

[0137] The term "pharmaceutically acceptable salts" as used herein refers to salts that are suitable for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic responses, etc., within the scope of sound medical judgment, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed from inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods known in the art, such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, hydrogensulfate, boronate, butyrate, camphorate, camphorsulfonate, succinate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, and the like. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N-alkyl salts. + (C 1-4 Alkyl) 4 -Representative alkali or alkaline earth metal salts include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, etc. When appropriate, further pharma-ceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations formed with counterions such as chloride, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkylsulfonates and arylsulfonates.

[0138] Pharmaceutical Compositions A pharmaceutical composition comprises one or more compounds described herein and one or more physiologically or pharma- ceutically acceptable carriers. The term "pharmaceutical acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, involved in carrying or transporting any subject composition or its components. Each carrier must be "acceptable" in the sense of being compatible with the subject composition and its components and non-toxic to the patient. Some examples of materials that can act as pharma- ceutically acceptable carriers are: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and (10) oils, such as soybean oil; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances used in pharmaceutical preparations.

[0139] The pharmaceutical composition of the present invention can also be administered locally or non-systemically, for example, topically or intradermally, especially when the target of treatment includes areas or organs that are easily accessible by local or non-systemic application, including the skin.Suitable local or non-systemic formulations are easily manufactured for administration to the skin.The pharmaceutical composition can be formulated as a lotion, cream, serum, spray, mousse, aerosol, emulsion, cake, ointment, gel, paste, patch, pencil, wet wipe, mask, stick, foam, elixir or concentrate.The pharmaceutical composition can be formulated to include a substance selected from foaming surfactants, vitamins, hydroxy acids, sunscreens, antioxidants, retinoids and moisturizers.

[0140] Exemplary Topical and Cosmetic Pharmaceutical Compositions The pharmaceutical compositions described herein can be formulated for topical administration. In some embodiments, the topical formulation is an emulsion, cream, lotion, gel, oil, ointment, aerosol spray or semi-solid formulation. In some embodiments, the topical formulation comprises a carrier selected from the group consisting of trehalose, maltodextrin, rice flour, microcrystalline cellulose, magnesium stearate, inositol, fructooligosaccharides, glucooligosaccharides, dextrose, sucrose, talc, water, saline, urea, methanol, ethanol, propanol, butanol, ethylene glycol, propylene glycol, white petrolatum, isopropyl myristate, lanonine, lanonine alcohol, mineral oil, lavender oil, nasturtium oil extract, sorbitan monooleate, cetylstearyl alcohol, hydroxypropyl cellulose, detergent, sucrose stearate, sucrose cocoate, sucrose distearate, 2-ethyl-1,3-hexanediol, polyoxypropylene-15-stearyl ether, glycerol stearate, glycerin, synthetic spermaceti, cetyl alcohol, butylparaben, propylparaben, and methylparaben.

[0141] The pharmaceutical compositions described herein may be formulated as cosmetic compositions. The cosmetic compositions may include a dermatologically acceptable vehicle. The dermatologically acceptable vehicle may include water, mineral oil, petrolatum, ceresin, lanonine alcohol, methylchloroisothiazolinone, and methylisothiazolinone. Examples of emollients that may be used as suitable dermatological carriers include, but are not limited to, stearyl alcohol, glycerol monostearate, glycerol monostearate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecane-2-ol, isocetyl alcohol, eicosanyl alcohol, benzyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, myristyl alcohol, glycerol monostearate ... Examples of emollients include isopropyl phosphate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanonine, cocoa butter, corn oil, cottonseed oil, tallow, lard, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil, soybean oil, sunflower seed oil, avocado oil, olive oil, sesame oil, coconut oil, peanut oil, castor oil, acetyl lanonine alcohol, petrolatum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, and myristyl myristate. Two or more emollients may be included in the composition. The dermatologically acceptable vehicle may be present in an amount of about 10% to about 99.999%, such as about 20% to about 99.999%, such as about 40% to about 90% by weight of the cosmetic composition. In some embodiments, the cosmetic composition also comprises water, up to about 98% by volume of the cosmetic composition, such as about 5% to about 80% by volume.

[0142] Examples of propellants that may be used as suitable dermatological carriers include, but are not limited to, liquefiable gas or halogenated propellants. Specific examples of propellants include dimethyl ether, trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethane, monochlorodifluoromethane, trichlorotrifluoroethane, propane, butane, carbon dioxide, nitrous oxide, or combinations thereof. The amount of propellant in the composition may be from about 10% to about 60% by weight of the composition.

[0143] Examples of solvents that may be used as suitable dermatological carriers include, but are not limited to, ethyl alcohol, methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethylsulfoxide, dimethylformamide, tetrahydrofuran, propylene glycol, butylene glycol, dipropylene glycol, ethoxylated or propoxylated diglycol, cyclic polyols, or combinations thereof.

[0144] Examples of emulsifiers that can be used as suitable dermatological carriers include nonionic, anionic or cationic emulsifiers.Suitable emulsifiers are disclosed, for example, in McCutcheon's Detergents and Emulsifiers, North American Edition, pp. 317-324 (1986) and ICI Handbook, pp. 1673-1686.Single-layer emulsion skin care products, such as oil-in-water and water-in-oil lotions and creams, are known in the cosmetic art and are useful in the present invention.Multi-layer emulsion compositions, such as the water-in-oil-in-water type disclosed in U.S. Patent Nos. 4,254,105 and 4,960,764, which teach emulsions and are incorporated herein by reference, are also useful in the present invention.In general, such single-layer or multi-layer emulsions include water, emollients and emulsifiers as essential ingredients. The composition comprises from about 1% to about 10% (e.g., from about 2% to about 5%) of an emulsifier. The emulsifier can be a microemulsion or a nanoemulsion.

[0145] Examples of powders used as suitable dermatological carriers include, but are not limited to, chalk, talc, fuller's earth, kaolin, starch, gum, colloidal silica sodium polyacrylate, tetraalkyl and / or trialkylaryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethylcellulose, ethylene glycol monostearate, or combinations thereof.

[0146] The cosmetic compositions described herein may contain additional oil-soluble and / or water-soluble materials that are conventionally used in compositions for use on skin, hair and nails.Specific examples of other suitable agents that may be included in the cosmetic compositions include moisturizers, humectants, surfactants, binders, thickeners, viscosity modifiers, buffers, preservatives, neutral or cationic lipids, lipid complexes, liposomes, polymers, sunscreens, lubricants, antioxidants, proteins, amino acids, fragrances, flavors, oils, natural extracts such as plant extracts, butters, vitamins, pH adjusters, absorbents, other dermatologically acceptable excipients and combinations thereof.

[0147] The cosmetic composition may comprise a moisturizing agent or humectant.In some examples, the cosmetic composition may be combined with other ingredients, such as moisturizing agents, cosmetic adjuvants, antioxidants, bleaching agents, darkening agents, anti-aging agents, hair removal agents, hair styling agents, nail styling agents, sunscreen agents, surfactants, bleaching agents, foaming agents, conditioner agents, moisturizing agents, fragrances, coloring agents, thickening agents, buffering agents, preservatives, etc., and mixtures thereof.The skin care composition containing these ingredients should be formulated so as not to affect the activity of the present compound, i.e., the compounds disclosed herein.

[0148] Examples of humectants include glycerol, sorbitol, propylene glycol, ethylene glycol, 1,3-butylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, allantoin, acetamine MEA, oat protein, hyaluronic acid, etc. They may be used alone or in combination. Preservatives may also be included in the cosmetic composition.

[0149] Preservatives are useful for substantially preventing microbial degradation. Examples of suitable preservatives include phenoxyethanol and parabens, such as methylparaben, ethylparaben and propylparaben; salicylic acid, chlorhexidine hydrochloride, phenoxyethanol, sodium benzoate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, isothiazolones, and the like. Other examples of preservatives are described in the International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen (CTFA, 7th ed., 1997), pp. 1654-55, hereinafter referred to as "Cosmetic Handbook". The composition may contain about 0.01% to about 20% by weight, (more preferably about 0.5% by weight> to about 5% by weight) of preservative. Microbial contamination can also be removed by gamma irradiation or microfiltration methods, or by brief heat treatments which do not result in the removal of protease inhibitor activity.

[0150] Examples of fragrances or odor masking agents that may be included in the disclosed compositions include menthol, anethole, carvone, eugenol, limonene, ocimene, n-decyl alcohol, citronellol, α-terpineol, methyl salicylate, methyl acetate, citronellyl acetate, cineole, linalool, ethyl linalool, vanillin, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, pimento oil, cinnamon leaf oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil, and the like.

[0151] Examples of surfactants that can be included in the disclosed compositions include sodium alkyl sulfates, such as sodium lauryl sulfate and sodium myristyl sulfate, sodium N-acylsarcosinates, such as sodium N-lauroyl sarcosinate and sodium N-myristoyl sarcosinate, sodium dodecylbenzenesulfonate, hydrogenated coconut fatty acid monoglyceride sodium sulfate, sodium lauryl sulfoacetate, and N-acylsglutamic acids, such as N-palmitoyl glutamic acid, sodium N-methylacyltaurate, sodium N-methylacylalanine, sodium α-olefinsulfonate, and sodium dioctyl sulfosuccinate. thorium;N-alkylaminoglycerols, such as N-lauryldiaminoethylglycerol and N-myristyldiaminoethylglycerol, N-alkyl-N-carboxymethylammonium betaine and sodium 2-alkyl-1-hydroxyethylimidazoline betaine;polyoxyethylene alkyl ethers, polyoxyethylene alkylaryl ethers, polyoxyethylene lanonyl alcohols, polyoxyethylene glyceryl mono fatty acid esters, polyoxyethylene sorbitol fatty acid esters, polyoxyethylene fatty acid esters, higher fatty acid glycerol esters, sorbitan fatty acid esters, PIURONIC TM type surfactants and polyoxyethylene sorbitan fatty acid esters, such as polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, and combinations thereof.

[0152] Examples of binders or thickeners include cellulose derivatives such as carboxymethylcellulose, methylcellulose, alkali metal salts of hydroxyethylcellulose and sodium carboxymethylhydroxyethylcellulose, alkali metal alginates such as sodium alginate, propylene glycol alginate, gums such as carrageenan, xanthan gum, tragacanth gum, karaya gum and gum arabic, and synthetic binders such as polyvinyl alcohol, sodium polyacrylate and polyvinylpyrrolidone. Viscosity agents that can be added to the composition to modify the viscosity include other polymers such as polyacrylates, e.g. polyacrylamides. Examples of other viscosity modifiers are described in the "Cosmetics Handbook", pages 1692-97, which is incorporated herein by reference in its entirety for its teaching of viscosity modifiers. To achieve the appropriate viscosity, the cosmetic composition includes from about 0.01% to about 20% by weight, e.g. from about 0.1% to about 5% by weight of a viscosity agent.

[0153] Coloring agents and fragrances can also be included in the composition comprising the compounds disclosed herein.The dermatologically acceptable vehicle can include emollients, diluents, solubilizers or emulsifiers, solvents, propellants, powders or combinations thereof.The cosmetic composition can also include moisturizing agents or humectants.In some embodiments, the cosmetic composition is an emulsion, cream, lotion, gel, oil, ointment, aerosol spray or semi-solid formulation.

[0154] Route of administration The selective PKCβ inhibitors described herein may be administered to a subject locally or non-systemically, e.g., topically, intradermally, subcutaneously. In some embodiments, the selective PKCβ inhibitors described herein are administered locally. In some embodiments, the selective PKCβ inhibitors described herein are administered intradermally. In some embodiments, the selective PKCβ inhibitors described herein are administered subcutaneously. In some embodiments, the selective PKCβ inhibitors described herein are administered by contacting a patch (containing said selective PKCβ inhibitor) to the skin (e.g., an area of ​​skin having a hyperpigmentation disorder or surrounding an area of ​​skin having a hyperpigmentation disorder).

[0155] In some embodiments, the method includes applying a selective PKCβ inhibitor to a predetermined area of ​​the body, e.g., a predetermined area of ​​the skin, e.g., as described herein. In some embodiments, the method includes applying a selective PKCβ inhibitor to an area of ​​the skin where a hyperpigmentation condition exists. In some embodiments, the method includes applying a selective PKCβ inhibitor to an area adjacent to an area of ​​the skin where a hyperpigmentation condition exists. In some embodiments, the method includes applying a selective PKCβ inhibitor to the face, arms, back, or other areas where unwanted or otherwise excessive hyperpigmentation exists.

[0156] Dosage Toxicity and therapeutic efficacy of selective PKCβ inhibitors, such as those described herein, can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. LD 50 is the dose that causes death in 50% of the population. 50 is the dose that is therapeutically effective in 50% of the population. The toxic-therapeutic dose ratio (LD 50 / ED 50 ) is the therapeutic index. Compounds that exhibit high therapeutic indices are preferred. Compounds that exhibit toxic side effects may be used, but care should be taken to design a delivery system that targets such compounds to affected areas of the skin in order to minimize potential damage to uninfected cells, thereby reducing side effects.

[0157] For any compound, the therapeutically effective dose can be estimated initially from cell culture assays (e.g., melanocyte, e.g., melanoma cell culture assays). IC determined in cell culture 50 A dose can be formulated in an animal model to achieve levels in the skin that include (i.e., the concentration of the test compound that achieves half-maximal inhibition of symptoms). Such information can be used to more accurately determine useful doses in humans. In addition, levels in plasma can be measured, for example, by high performance liquid chromatography, to confirm systemic exposure.

[0158] It should also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors including the activity of the particular compound used, age, size of the lesion, number of lesions, general health, sex, dietary habits, time of administration, drug combinations, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of selective PKCβ inhibitor in the composition, such as a selective PKCβ inhibitor described herein, will also depend on the particular selective PKCβ inhibitor in the composition.

[0159] Treatment In another aspect, the invention provides a method of treating a subject having a hyperpigmentation disorder (e.g., melasma), comprising administering to the subject an effective amount of a selective PKCβ inhibitor, e.g., a selective PKCβ inhibitor described herein, e.g., ruboxistaurin, e.g., locally or non-systemically, e.g., topically or intradermally, thereby treating the subject.

[0160] In some embodiments, the method includes administering the selective PKCβ inhibitor to the subject daily, every other day, weekly or monthly.In some embodiments, the method includes administering the selective PKCβ inhibitor to the subject about twice a day, about once a day, about every 2 days, about every 3 days, about every 4 days, about every 5 days, about every 6 days, about once a week, about every other week, for example, once every 2 weeks, about once a month, for example, monthly.In some embodiments, the subject has been administered one or more previous doses of the compound, for example, at least 2, 10, 20, 30, 40, 50, 100, 200, 300 or 500 doses of the compound.In some embodiments, the subject has been previously treated with the compound, for example, at least 1 month, 6 months, 12 months, 24 months, 36 months or 48 months. In certain embodiments, the methods include sequential administration of one or more selective PKCβ inhibitors, e.g., the subject is administered at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 50, or 100 times. In certain embodiments, the methods include sequential administration of one or more selective PKCβ inhibitors, e.g., the subject is administered at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 50, or 100 times. In certain embodiments, the methods include administering to the subject a selective PKCβ inhibitor about every hour, about every 2 hours, about every 3 hours, about every 4 hours, e.g., about 3-4 times per day.

[0161] Hyperpigmentation Disorders The selective PKCβ inhibitors described herein can be used to treat hyperpigmentation disorders, such as skin hyperpigmentation disorders, such as melasma. In some embodiments, the hyperpigmentation disorder is melasma. In some embodiments, the hyperpigmentation disorder is post-inflammatory hyperpigmentation. In some embodiments, the hyperpigmentation disorder is lentigo (e.g., age spots). In some embodiments, the hyperpigmentation disorder is associated with ultraviolet (UV) exposure, such as sun exposure or sunburn reaction. In some embodiments, the hyperpigmentation disorder is sunburn reaction. In certain embodiments, the hyperpigmentation condition is selected from melasma, post-inflammatory hyperpigmentation, discoid lupus erythematosus, phytophotodermatitis, lentigines (e.g., senile lentigo), birthmarks, cafe au lait spots, acanthosis nigricans, burn-associated hyperpigmentation, lentigines, drug-induced hyperpigmentation (e.g., sulfonamide-, tetracycline-, NSAID-, barbiturate-, and carbamazepine-induced hyperpigmentation), injury-induced hyperpigmentation, primary biliary cirrhosis-associated hyperpigmentation, Addison's disease-associated hyperpigmentation, pigmented nevi, ephelides, seborrheic keratosis, skin cancer-associated hyperpigmentation, infection-associated hyperpigmentation (e.g., tinea versicolor, erythrasma), eczema, photocontact dermatitis, ichthyosis, neurofibromatosis, or hyperpigmentation associated with ultraviolet (UV) radiation, e.g., sun exposure or sunburn reaction.

[0162] In some embodiments, the disorder is other than an age-related disorder.

[0163] Combination Treatment The selective PKCβ inhibitors described herein may be administered in combination with one or more additional agents, such as therapeutic agents.The one or more additional agents may include, but are not limited to, hydroquinone, tretinoin, corticosteroids, azelaic acid, kojic acid, retinoids, glycolic acid, L-ascorbic acid, sunscreens, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide and titanium dioxide.The selective PKCβ inhibitors described herein may be administered in combination with previous Fraxel laser treatment, tape stripping or chemical removal of the stratum corneum.These treatments improve the penetration of the selective PKCβ inhibitors described herein. EXAMPLES

[0164] The following examples are intended to be illustrative and not limiting in any way.

[0165] Example 1. Efficacy of the selective PKCβ inhibitor ruboxistaurin in lightening pigmentation Previous studies have shown that the non-selective PKC inhibitor bisindolylmaleimide (Bis) PKC-β inhibits the phosphorylation of tyrosinase, the rate-limiting enzyme in melanogenesis, thereby reducing its activity (e.g., Park et al. (2004) J of Investigative Dermatology 122: 159-166; U.S. Pat. No. 5,962,417). Because PKC-β appears to function exclusively in the skin as an activator of tyrosinase, whereas other PKC isoforms play multiple roles in the skin, agents for lightening skin wounds would preferably selectively inhibit the β isoform (e.g., to reduce safety and side effects, among other things). The following example shows the efficacy of the selective PKCβ inhibitor ruboxistaurin in lightening pigmentation.

[0166] Briefly, 8-9 week old C47 ΒI / 6 mice (3 mice / group) were depilated to remove hair on their backs. These mice have black hair but no melanin pigmentation in the skin. Melanocytes in hair follicles are responsible for hair color. Topical formulations (DMSO:propylene glycol / 25:75) containing 4% hydroquinone (HQ), 100 μm (0.0057%) Bis or 100 μm (0.0057%) ruboxistaurin were prepared for administration. All compounds and vehicle were applied daily to the depilated area for 19 days after depilation, the period during which new hair shafts are produced after depilation. Representative hairs of each type (guard, awl (large follicles deep in the dermis or subcutaneous follicles), auchene and zig-zag (smaller follicles in the more superficial dermis, the most common hair color) were randomly plucked (50 hairs / mouse) and photographed under a surgical microscope. In a separate analysis, 20 dark and light colored hairs from each mouse were subjected to a computer-assisted analysis of the "gray value" for the pixel containing the hair shaft.

[0167] As shown in Figure 1, awl hairs showed moderate differences in color with little color diversity within each group, and all experimental groups appeared lighter than the control group (Figure 1A and B). Zig-zag hairs treated with 4% HQ showed minimal color difference compared to vehicle controls, while both Bis- and ruboxistaurin-treated hairs were notably lighter in color and highly variable (Figure 1A, C and D). The average shade value within the hair shaft was determined using ImageJ (NIH) software. The shade value is the sum of the shade values ​​of all pixels in the hair shaft divided by the number of pixels; values ​​range from 0 (white, no pigment) to 255 (black). Awl hairs showed a mean decrease in shade value of 168 for 4% HQ, 168 for Bis, and 155 for ruboxistaurin, compared to a control value of 181. Zig-zag hair also showed a significant mean decrease in shade value in all groups treated with 4% HQ: 156; Bis: 127; and Ruboxistaurin: 134 compared to control: 159 (Figure 2).

[0168] Further comparisons of the zig-zag hairs in each group shown below with the median shade values ​​above were performed to determine the maximum degree of hair lightening (attributable to maximum drug exposure). This analysis yielded low variability (smaller standard deviations) in all groups and highly statistically significant differences between groups. Hairs treated with 4% HQ were slightly lighter than the control group, while ruboxistaurin-treated hairs were lighter than both the control and 4% HQ hairs (Figure 3). Overall, the in vivo experimental data described herein demonstrated that ruboxistaurin is not only an effective lightening agent, but is also significantly more potent (e.g., at a 0.0057% concentration) as a lightening agent than HQ (e.g., at a 4.0% concentration, which is the standard concentration used in current prescription skin lightening products).

[0169] Example 2: Clinical trial evaluating ruboxistaurin gel in ultraviolet light-induced melanogenesis in healthy volunteers A clinical trial was conducted to evaluate the ability of ruboxistaurin or placebo gel formulations to inhibit ultraviolet (UV) light-induced melanogenesis in healthy volunteers. The ruboxistaurin formulations used in the trial included 0.1%, 0.5%, and 1.0% ruboxistaurin gels. One of the objectives of the trial was to determine whether topical administration of ruboxistaurin gel could inhibit UV light-induced melanogenesis.

[0170] Clinical trial design Each subject had 5 treatment sites. Four sites were administered with ruboxistaurin gel or vehicle, and one site was left untreated. The ruboxistaurin used in the trial was 0.1%, 0.5% and 1.0% ruboxistaurin gel. Subjects, e.g., healthy volunteers, were administered 3 minimal erythema doses (MEDs) of UV radiation, i.e., a UV dose that would produce erythema, e.g., sun dermatitis, and a tan color after a few days, which is approximately equivalent to exposure to 1-2 hours of midday sunlight in spring. Each UV exposure was performed at a minimal erythema dose (MED). After the three MED UV exposures, the subjects were administered ruboxistaurin gel or vehicle at 4 sites. All 5 sites, including the 4 treated sites and the 1 UV-irradiated but untreated site, were kept under occlusion for 15 days.

[0171] The primary predetermined endpoint of the study was the Individual Typology Angle (ITA) colorimeter reading obtained on day 24, when all erythema, e.g., sun dermatitis, was predicted to have disappeared. A colorimeter was used to quantitatively measure skin color, e.g., erythema or pigmentation. Pigmentation was measured using the Individual Typology Angle (ITA), where a lower number indicates a darker, e.g., more tanned, test area.

[0172] Secondary endpoints of the study included ITA colorimeter readings on days 7, 14, and 17; Investigator Dynamic Grading Assessment (IDGA) scores on days 7, 14, and 17; and biopsy for melanin on day 24. The Investigator Dynamic Grading Assessment (IDGA) score is a measure used to assess color in the skin by a blinded observer, with higher numbers indicating darker test areas, as shown in Table 1. [Table 1]

[0173] On day 1, all subjects enrolled in the study were examined for non-identical skin tone and blemishes using a Wood's lamp at the following sites: the back between the waist and shoulder blades. For MED dose application, six UV doses were applied chronologically to the left side of the mid-back using a multi-hole solar simulator, increasing in 25% increments. A Duoderm dressing was applied to the right side of the back. The test areas were graded for pigmentation, erythema, and colorimetric readings were obtained. Five test articles, namely, ruboxistaurin gel, were applied to each subject. Subjects were then instructed to avoid UV exposure, photosensitizers, antihistamines, anti-inflammatory drugs, and other prohibited medications, and to return to the study facility 16-24 hours after completion of UV exposure for the determination of each subject's MED dose.

[0174] Ruboxistaurin gel was applied to a metal test container (inner diameter φ12 mm, outer diameter φ14 mm) placed in a hole punched in a hydrocolloid dressing (DuoDerm). Approximately 200 μl of five test articles were pipetted onto filter paper placed in the test container. The Duoderm dressing, with 6x15 mm holes at least 1.5 cm apart, was secured to the skin with adhesive tape with identical holes. The container itself was secured in place with adhesive tape and removed before each new application. Remaining sample residue was removed by gently cleaning each test area with soft tissue before each new application. The hydrocolloid dressing remained in place until the sites were evaluated on days 7, 14, and 17, but was replaced more frequently when necessary. On days when no treatment / evaluation was performed, subjects were instructed to keep the container and patch intact until they returned to the clinical center. Subjects returned to the clinical center for their next scheduled dosing opportunity.

[0175] On the second day, reactions to UV exposure were graded by an experienced assessor under warm fluorescent or tungsten lighting at least 450 lux. The grading scale for erythema response to UV exposure is shown in Table 2. The MED was defined as the first exposure site in the series that produced an erythema grade of at least 2. Three MEDs of UV exposure were applied to each of five sites on the right side of the back. Ruboxistaurin gel was applied immediately after UV exposure. [Table 2]

[0176] On days 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 15, and 16, the previously applied ruboxistaurin gel was removed. The test sites were evaluated for signs and symptoms of irritation, after which the ruboxistaurin gel was reapplied.

[0177] On days 7, 14, 17, and 24, the previously applied ruboxistaurin gel was removed and the Duoderm dressing was removed. After 15 minutes, the test sites were evaluated for signs and symptoms of irritation. Erythema and pigment darkening were then graded and colorimeter measurements were performed. Cross-polarized and non-polarized digital images of each test site were taken. The Duoderm dressing and ruboxistaurin gel were reapplied on days 7 and 14. Ruboxistaurin gel was not applied on days 17 and 24. After all measurements were taken on day 24, skin biopsies were obtained from five sites.

[0178] result ITA readings obtained from all subjects showed that the majority of test areas, e.g., areas that received ruboxistaurin gel, were brighter than placebo on days 7, 14, 17, and 24, as summarized in Table 3. On day 7, 9 / 12 test areas that received 0.1% or 0.5% ruboxistaurin gel were brighter than placebo (p value 0.07); 7 / 12 test areas that received 1.0% ruboxistaurin gel were brighter than placebo. On day 14, 9 / 12 test areas that received 0.1% ruboxistaurin gel were brighter than placebo (p value 0.07); 7 / 12 and 8 / 12 test areas that received 0.5% or 1.0% ruboxistaurin gel, respectively, were brighter than placebo. On day 17, 9 / 12 test areas receiving 0.1%, 0.5% or 1.0% ruboxistaurin gel were lighter than placebo (p value 0.07). On day 24, 6 / 12 test areas receiving 0.1% ruboxistaurin gel, 9 / 12 test areas receiving 0.5% ruboxistaurin gel and 7 / 12 test areas receiving 1.0% ruboxistaurin gel were lighter than placebo. [Table 3]

[0179] As shown in Figure 4, IDGA assessments of all test areas in subjects on days 7, 14, 17 and 24 showed statistically significant (p<0.05) less pigmentation, e.g., lighter skin, in the test areas where ruboxistaurin gel was applied versus placebo. Lower IDGA values ​​indicate less pigmentation (see Table 2 above). This reduced pigmentation was most noticeable on days 17 and 24 after UV exposure when erythema, e.g., sun dermatitis, had completely disappeared and did not compete with the investigator's perception of browning (sunburn).

[0180] All doses of ruboxistaurin gel tested in this study were well tolerated under occlusion. No toxicity, application site reactions or irritation were observed in any subject.

[0181] The results from this trial suggest that in some embodiments, topical application of a ruboxistaurin gel formulation, such as at least 0.1% ruboxistaurin gel, can reduce skin darkening and pigmentation, such as melanogenesis, induced, for example, by UV radiation. In some embodiments, topical application of a ruboxistaurin gel formulation, such as at least 0.1% ruboxistaurin gel, can result in a decrease in tyrosinase production of melanin.

[0182] Inclusion by reference All publications and patents mentioned in this specification are herein incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.

[0183] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the following claims. Furthermore, the present invention includes the following aspects. Item 1. A method for reducing skin pigmentation in a subject, comprising non-systemically (e.g., topically, intradermally or subcutaneously) administering to the subject an effective amount of a compound that selectively inhibits PKCβ, thereby reducing skin pigmentation in the subject. Item 2. The method of Item 1, wherein reducing skin pigmentation comprises reducing skin pigmentation associated with a skin hyperpigmentation condition. Item 3. The method of item 1, wherein reducing skin pigmentation includes reducing healthy or non-disease state skin pigmentation, for example unwanted healthy skin pigmentation. Item 4. The method of any one of items 1 to 3, wherein the compound comprises a compound of formula I (eg, as described herein). Clause 5. The method of clause 1, wherein the compound comprises a compound of formula Id (eg, as described herein). Item 6. The method of item 1, wherein the compound comprises a compound of formula If-1 (eg, as described herein). Item 7. The method of item 1, wherein the compound comprises a compound of formula If-2 (eg, as described herein). Item 8. The method according to Item 1, wherein the compound comprises ruboxistaurin or a salt thereof. Item 9. The method of item 1, wherein the compound comprises ruboxistaurin mesylate. Item 10. The method according to item 8 or 9, wherein the compound administered to the subject comprises ruboxistaurin or a salt thereof, such as ruboxistaurin mesylate, at a dose of at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5%. Item 11. The method according to any one of items 1 to 10, wherein the compound is administered locally. Item 12. The method according to any one of items 1 to 10, wherein the compound is administered intradermally. Item 13. The method according to any one of items 1 to 10, wherein the compound is administered subcutaneously. Item 14. The method of any of items 1 to 13, wherein administering comprises contacting a device, such as a dermal patch, containing the compound to the subject, such as the skin of the subject. Item 15. The method according to any one of items 1 to 14, wherein the compound is administered in a pharmaceutical composition, such as a topical formulation (eg, a gel). Clause 16. The method of clause 2, wherein the hyperpigmentation condition is selected from melasma, post-inflammatory hyperpigmentation, discoid lupus erythematosus, phytophotodermatitis, lentigines (e.g., senile lentigo), birthmarks, cafe au lait spots, acanthosis nigricans, burn-associated hyperpigmentation, drug-induced hyperpigmentation (e.g., sulfonamide-, tetracycline-, NSAID-, barbiturate-, and carbamazepine-induced hyperpigmentation), injury-induced hyperpigmentation, primary biliary cirrhosis-associated hyperpigmentation, Addison's disease-associated hyperpigmentation, pigmented nevi, ephelides, seborrheic keratosis, skin cancer-associated hyperpigmentation, infection-associated hyperpigmentation (e.g., tinea versicolor, erythrasma), eczema, photocontact dermatitis, ichthyosis, neurofibromatosis, or hyperpigmentation associated with ultraviolet (UV) radiation, e.g., sun exposure or sunburn reaction. Item 17. The method of item 2, wherein the hyperpigmentation condition is melasma. Item 18. The method of item 2, wherein the hyperpigmentation condition is post-inflammatory hyperpigmentation. Item 19. The method of item 2, wherein the hyperpigmentation condition is a lentigo (e.g., age spots). Item 20. The method according to item 2, wherein the hyperpigmentation condition is a sunburn reaction. Item 21. The method according to any one of items 1 to 20, wherein the compound is administered in combination with a further agent, such as a therapeutic or cosmetic agent. Clause 22. The method of clause 21, wherein the further agent, e.g., therapeutic agent, is selected from one or more of hydroquinone, tretinoin, corticosteroids, azelaic acid, kojic acid, retinoids, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide, titanium dioxide, cosmetic agents, pigments, fragrances, sunscreens, foaming surfactants, vitamins, hydroxy acids, antioxidants, retinoids, or moisturizers. Item 23. The method of item 21 or 22, wherein the additional agent is administered locally. Item 24. The method according to any one of items 21 to 23, wherein a further agent is co-applied with the compound. Item 25. The method of any of items 21 to 23, wherein the further agent and the compound are applied to a common area at different times. Item 26. The method according to any one of items 21 to 24, wherein the additional agent and the compound are contained in the same unit dosage form. Item 27. The method according to any one of items 21 to 26, wherein the additional agent and the compound are processed into different unit dosage forms. Item 28. The method of any of items 21 to 27, wherein a second or multiple additional agents are administered. Item 29. The method according to any one of items 1 to 28, comprising a second administration of the compound. Item 30. The method according to any one of items 1 to 29, comprising a third administration of the compound. Item 31. The method according to any one of items 1 to 30, comprising administering the compound multiple times within a 7-day period, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. Item 32. The method according to any one of items 1 to 31, comprising administering the compound multiple times within a 14-day period, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. Item 33. The method according to any one of items 1 to 32, comprising administering the compound multiple times within a 21-day period, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more times. Item 34. The method according to any one of items 1 to 33, comprising administering the compound multiple times within a 30-day period, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, or 15 or more. Item 35. The method according to any one of items 1 to 34, wherein the compound is administered daily, every other day, weekly or monthly. Clause 36. The method of any of clauses 1 to 35, wherein the compound is administered daily for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months or longer. Item 37. The method of any of items 1 to 36, wherein the compound is administered daily for at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 years per year. Item 38. The method according to any one of items 1 to 37, wherein the subject has previously been treated with the compound, for example for at least 1 month, 6 months, 12 months, 24 months, 36 months or 48 months. Clause 39. The method according to any one of clauses 1 to 38, wherein the subject has received one or more previous administrations of the compound, for example at least 2, 10, 20, 30, 40, 50, 100, 200, 300 or 500 administrations of the compound. Item 40. The method of any one of items 1 to 39, comprising applying the compound to a predetermined area of ​​the body, such as a predetermined area of ​​the skin. Item 41. The method of any one of items 1 to 40, comprising applying a compound to an area of ​​skin having a hyperpigmentation condition. Item 42. The method of any one of items 1 to 41, comprising applying the compound to an area adjacent to an area of ​​skin having a hyperpigmentation condition. Item 43. A method according to any one of items 1 to 42, comprising applying the compound to the face, arms, back or other areas where there is unwanted or otherwise excessive hyperpigmentation. Item 44. A method for reducing skin pigmentation associated with a skin hyperpigmentation condition in a subject, comprising topically administering an effective amount of ruboxistaurin or a salt thereof to an area of ​​the subject's skin (e.g., a predetermined area of ​​the subject's skin), thereby reducing the subject's skin pigmentation compared to the skin pigmentation prior to administration of ruboxistaurin or a salt thereof. Clause 45. The method of clause 44, wherein the hyperpigmentation condition comprises melasma. Item 46. A method for reducing healthy pigmentation in an area of ​​a subject's skin, comprising topically administering an effective amount of ruboxistaurin or a salt thereof to an area of ​​the subject's skin (e.g., a predetermined area of ​​the subject's skin), thereby reducing the subject's skin pigmentation compared to the skin pigmentation prior to administration of ruboxistaurin or a salt thereof. Item 47. A pharmaceutical composition for use in the method according to any one of items 1 to 46. Item 48. The pharmaceutical composition according to Item 47, which is formulated as a lotion, cream, serum, spray, mousse, aerosol, emulsion, cake, ointment, gel, paste, patch, pencil, wet tissue, mask, stick, foam, elixir or concentrate. Item 49. The pharmaceutical composition according to Item 47, which is formulated as a gel. Item 50. The pharmaceutical composition according to Item 47, further comprising a therapeutic agent selected from the group consisting of hydroquinone, tretinoin, corticosteroids, azelaic acid, kojic acid, retinoids, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide, titanium dioxide, cosmetic agents, pigments, fragrances, sunscreens, foaming surfactants, vitamins, hydroxy acids, antioxidants, retinoids or moisturizers. Item 51. A method comprising non-systemically (e.g., topically, intradermally or subcutaneously) applying an effective amount of a compound that selectively inhibits PKCβ to a subject's skin-bearing hair (e.g., at the follicular orifice surrounding the growing hair shaft), thereby reducing pigmentation of the growing hair (e.g., reducing pigmentation compared to the subject's non-growing hair). Item 52. The method of item 51, wherein the subject has artificially colored, e.g. dyed, hair. Clause 53. The method of clause 51, wherein the compound is administered in a regimen effective to reduce differences in color or shade of new growth of the hair shaft in a subject having, for example, artificially colored, e.g., dyed, hair. Item 54. The method according to any one of items 51 to 53, wherein the interval, e.g. the period, between reapplications, of an artificial color, e.g. dye, is extended, e.g., the hair. Clause 55. The method of clause 54, wherein the interval is extended to at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks or 8 weeks. Clause 56. The method of clause 51, wherein the compound comprises a compound of formula I (eg, as described herein). Clause 57. The method of clause 51, wherein the compound comprises a compound of formula Id (eg, as described herein). Clause 58. The method of clause 51, wherein the compound comprises a compound of formula If-1 (eg, as described herein). Clause 59. The method of clause 51, wherein the compound comprises a compound of formula If-2 (eg, as described herein). Item 60. The method of item 51, wherein the compound comprises ruboxistaurin or a salt thereof. Item 61. The method of item 51, wherein the compound comprises ruboxistaurin mesylate. Item 62. The method of item 60 or 61, wherein the compound administered to the subject comprises a dose of at least 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5% ruboxistaurin or a salt thereof, such as ruboxistaurin mesylate. Item 63. The method of item 51, wherein the compound is administered locally. Item 64. The method of item 51, wherein the compound is administered intradermally. Item 65. The method of item 51, wherein the compound is administered subcutaneously. Item 66. The method of any one of items 51 to 65, wherein the compound is administered in a pharmaceutical composition, such as a topical formulation (eg, a gel). Item 67. The method of any of items 1 to 66, wherein the compound reduces, eg, inhibits, melanogenesis, eg, skin darkening and pigmentation. Clause 68. The method of clause 67, wherein melanogenesis is induced, for example, by UV exposure, such as sun exposure or a tanning reaction. Item 69. The method of item 67 or 68, wherein the compound comprises a compound of formula I, a compound of formula Id, a compound of If-1, a compound of If-2, ruboxistaurin or a salt thereof, such as ruboxistaurin mesylate, formulated as a gel. Clause 70. The method of clause 69, wherein the gel formulation comprises at least 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5% dosage of ruboxistaurin or a salt thereof, such as ruboxistaurin mesylate. Paragraph 71. The method of any of paragraphs 67 to 70, wherein the compound reduces, e.g. inhibits, melanogenesis, e.g. skin darkening and pigmentation, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100%. Item 72. The method of any of items 67 to 71, wherein the reduction, e.g. inhibition, of melanin formation is measured by the assay of Example 2. Item 73. A unit dosage form or formulation comprising an effective amount of a compound that selectively inhibits PKCβ formulated for non-systemic administration. Clause 74. The unit dosage form or formulation of clause 73, wherein the compound comprises a compound of formula I (eg, as described herein). Clause 75. The unit dosage form or formulation of clause 73, wherein the compound comprises a compound of formula Id (eg, as described herein). Item 76. The unit dosage form or formulation of Item 73, wherein the compound comprises ruboxistaurin or a salt thereof, such as ruboxistaurin mesylate. Item 77. The unit dosage form or formulation of Item 73, wherein the compound comprises ruboxistaurin mesylate. Item 78. A unit dosage form or formulation according to any one of items 73 to 77 for topical use. Item 79. The unit dosage form or formulation according to any one of items 73 to 78, which is formulated as a gel. Item 80. A unit dosage form or formulation according to any one of items 73 to 79, which when administered to a subject reduces, e.g. inhibits, melanogenesis, e.g., skin darkening and pigmentation. Clause 81. The unit dosage form or formulation of clause 80, wherein melanogenesis is induced, for example, by UV exposure, such as sun exposure or a tanning reaction. Item 82. The unit dosage form or formulation according to any one of items 73 to 81, wherein the compound comprises a compound of formula I, a compound of formula Id, a compound of formula If-1, a compound of formula If-2, ruboxistaurin or a salt thereof, such as ruboxistaurin mesylate formulated as a gel. Item 83. The unit dosage form or formulation of item 82, wherein the gel formulation comprises at least 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% or 1.5% dosage of ruboxistaurin or a salt thereof, such as ruboxistaurin mesylate. Item 84. A unit dosage form or formulation according to any one of items 73 to 83, which reduces, e.g. inhibits, melanogenesis, e.g., skin darkening and pigmentation, by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100%. Item 85. A first unit dosage form comprising an effective amount of a compound that selectively inhibits PKCβ formulated for non-systemic administration; and A second unit dosage form comprising an effective amount of an additional agent, such as a therapeutic or cosmetic agent. 16. A set of unit dosage forms comprising: Clause 86. The set according to clause 85, wherein the further agent is selected from hydroquinone, tretinoin, corticosteroids, azelaic acid, kojic acid, retinoids, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide, titanium dioxide, cosmetic agents, pigments, fragrances, sunscreens, foaming surfactants, vitamins, hydroxy acids, antioxidants, retinoids or moisturizers.

Claims

1. 1. A composition comprising ruboxistaurin or a salt thereof for treating hyperpigmentation in a subject, the composition further comprising an antioxidant and / or a glycol.

2. 2. The composition of claim 1, wherein ruboxistaurin or a salt thereof is present in the composition at 0.1% to 1.5% by weight.

3. The composition of claim 2, wherein ruboxistaurin or a salt thereof is present in the composition at 0.1% to 1% by weight.

4. 4. The composition of claim 3, wherein ruboxistaurin or a salt thereof is present in the composition at 0.8% by weight.

5. The composition of any one of claims 1 to 4, wherein the ruboxistaurin or a salt thereof comprises ruboxistaurin mesylate.

6. A composition according to any one of claims 1 to 5, wherein the antioxidant is present in the composition in an amount of from 0.01% to 20% by weight.

7. A composition according to any one of the preceding claims, wherein the glycol is present in the composition at from 40% to 90% by weight.

8. The composition of any one of claims 1 to 7, formulated as a lotion, cream, serum, spray, mousse, aerosol, emulsion, cake, ointment, gel, paste, patch, pencil, wipe, mask, stick, foam, elixir or concentrate.

9. The composition of claim 8 , wherein the composition is formulated as a gel.

10. 10. The composition of any one of claims 1 to 9, further comprising an additional therapeutic agent selected from hydroquinone, tretinoin, a corticosteroid, azelaic acid, kojic acid, a retinoid, glycolic acid, L-ascorbic acid, p-aminobenzoic acid, padimate O, phenylbenzimidazole sulfonic acid, cinoxate, anthranilic acid, dioxybenzone, oxybenzone, avobenzone, octisalate, octocrylene, octyl methoxycinnamate, homosalate, octinosate, sulisobenzone, trolamine salicylic acid, ecamsule, zinc oxide, titanium dioxide, cosmetic agents, pigments, fragrances, sunscreens, foaming surfactants, vitamins, hydroxy acids, antioxidants, retinoids or moisturizers.

11. The composition of claim 10 , wherein the additional agent is formulated for topical use.

12. 12. The composition of any one of claims 1 to 11, wherein treating the hyperpigmentation condition comprises treating pigmentation associated with a skin hyperpigmentation condition or skin pigmentation in a healthy or non-disease state.

13. Treating hyperpigmentation conditions includes treating hyperpigmentation associated with skin hyperpigmentation conditions, including but not limited to melasma, post-inflammatory hyperpigmentation, discoid lupus erythematosus, phytophotodermatitis, lentigines (e.g., senile lentigo), birthmarks, cafe au lait spots, acanthosis nigricans, burn-associated hyperpigmentation, drug-induced hyperpigmentation (e.g., sulfonamide-, tetracycline-, NSAID-, barbiturate-, and carbamazepine-induced hyperpigmentation).

13. The composition of claim 12, wherein the hyperpigmentation is selected from hyperpigmentation associated with skin cancer, skin ulcers, psoriasis, eczema, photocontact dermatitis, ichthyosis, neurofibromatosis, and hyperpigmentation associated with ultraviolet (UV) light exposure, e.g., sun exposure or sunburn reaction.

14. (i) a predetermined area of ​​skin; (ii) areas of the skin with hyperpigmentation; (iii) an area adjacent to an area of ​​skin having a hyperpigmentation condition; and / or (iv) The face, arms, back or other areas where there is unwanted or otherwise excessive hyperpigmentation The composition according to claim 13,

15. (i) a second use of the composition; (ii) a third use of the composition; (iii) Multiple use within a seven-day period; (iv) Multiple use within a 14-day period; (v) Multiple use within a 21-day period; or (vi) Multiple use within a 30-day period The composition according to any one of claims 1 to 14, comprising:

16. The composition comprises: (i) daily, every other day, weekly or monthly; (ii) For at least one month; or (iii) For at least one year; The composition according to any one of claims 1 to 15,

17. The composition of any one of claims 1 to 16, wherein the subject has previously been treated with the composition.

18. 18. The composition of any one of claims 1-11 and 15-17, wherein treating the hyperpigmentation condition comprises treating hyperpigmentation of growing hair of a subject, wherein the composition is applied topically to hair bearing skin of the subject.

19. (i) the subject has artificially colored hair; (ii) the composition is used in a regimen effective to reduce the difference in color or shade between the newly growing hair shaft portion and the previous hair shaft portion; and / or (iii) use of the composition extends the time between applications of artificial coloring to the hair, in some cases by at least one week; The composition of claim 18.

20. Use of a compound in the manufacture of a therapeutic or cosmetic composition for treating hyperpigmentation of growing hair in a subject, said compound comprising ruboxistaurin or a salt thereof and further comprising an antioxidant and / or a glycol.

21. 16. Use of a compound in the manufacture of a therapeutic or cosmetic composition for treating hyperpigmentation in a subject, said compound comprising ruboxistaurin or a salt thereof and further comprising an antioxidant and / or a glycol.

22. The composition according to any one of claims 1 to 19, wherein the composition is a topical composition.

23. The composition according to any one of claims 1 to 19 and 22, wherein the composition is used topically.

24. 22. The use according to claim 20 or 21, wherein the composition is applied topically.

Citation Information

Patent Citations

  • MELANIN SYNTHESIS REGULATION METHOD

    JP2000509251A

  • Therapeutic treatment for skin diseases

    JP2002501501A

  • Nucleotides modulating the expression of protein-kinase cbeta-1 isoforms and their use as skin depigmenting agents

    JP2007516715A

  • Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases

    US20050074497A1